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1. General introduction 
1.1. Epidemiology of breast cancer 
With approximately 70,000 new cases per year, breast cancer is by far the 
most common cancer in women (Figure 1) in Germany ("Krebs in Deutschland 
2009/2010," 2013). Additionally, there are about 6,500 ductal carcinomata in situ, a 
pre-cancer form of breast cancer. Based on current incidence rates, about one in 
eight women is diagnosed with breast cancer during their lifetime. Approximately 
every fourth patient is younger than 55 at diagnosis; one in ten is under 45 years old. 
Despite the increase in incidence rates, today fewer women die from breast cancer. 
Overall, the age-standardized 5-year relative survival rate was 83%, based on data 
Figure 1. Percentage of the most common tumor types of women in all new cancer cases in 
Germany 2010 (adapted from Krebs in Deutschland 2009/2010. (2013)) 
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from the Cancer Registry of several states, which included female patients diagnosed 
with invasive breast cancer between 2000 and 2009 (Figure 2). 
In 30 European countries breast cancer mortality has declined in median of 
19% in the years from 1989 to 2006 (Autier et al., 2010). The chances of survival 
have improved significantly due to advances in cancer therapy. But these treatments 
leave patients with many side effects that affect their quality of life, and a persistently 
unhealthy lifestyle (e.g. smoking, alcohol consumption, low physical activity, obesity) 
can lead to earlier non-breast-cancer-specific and breast-cancer-specific mortality 
(Villasenor et al., 2012). Some side effects can be solved with the help of targeted 
medicine. But there are many adverse effects which can best be solved by physical 
exercise. This must be tested in exercise-oncology research. 
 
Figure 2. Relative survival rate after primary breast cancer diagnosis, Germany 2009-2010 (adapted 
from Krebs in Deutschland 2009/2010. (2013)) 
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1.2. Exercise-oncology research 
Significant progress has been made in the field of exercise-oncology research 
over the past three decades. Epidemiological studies observed that physical activity 
has salutary benefits in patients undergoing cancer therapy, producing improvements 
in their quality of life (Ulrich, Steindorf, & Berger, 2012). Additionally, observational 
studies in this field show a reduced risk of recurrence, and they associate physical 
activity with improved overall survival before the diagnosis and even after (see Figure 
3) (Ballard-Barbash et al., 2012; Schmidt, Chang-Claude, et al., 2013). However, a 
systematic review showed some evidence that breast cancer specific survival rates 
can be associated with exercise only after diagnosis (Ibrahim & Al-Homaidh, 2011). 
Schmid and Leitzmann’s meta-analysis (Schmid & Leitzmann, 2014) indicated that 
moderate physical activity of 150 min/week after diagnosis is associated with a 24% 
reduction in total mortality among breast cancer survivors and a 28% decreased risk 
of total mortality. So far we had aforementioned observational studies that provided 
information about survival outcome. But only intervention trials are able to show proof 
Figure 3. Forest plot of risk estimates from observational studies of physical activity and mortality 
outcomes in breast cancer survivors. (Ballard-Barbash 2012) 
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of causality and explain the underlying mechanisms and benefit of exercise therapy 
in cancer patients. According to Friedenreich et al. (2001) recommendations for more 
evidence, which can be emerged from randomized controlled trials (RCT) in this field, 
in the last decade more RCT have been done, which give the next level of scientific 
evidence to develop public health recommendations on exercise therapy for cancer 
patients. Overall the study quality needs to be improved. Jones and Alfano (2013) 
summarized and listed future prospects in a recent review about the ongoing studies 
examining exercise across the cancer experience in this field. 
Based on a framework entitled Physical Exercise Across the Cancer 
Experience (PEACE) time point (Figure 4) (Courneya & Friedenreich, 2001), the 
authors mention some major gaps in current knowledge. They identified a total of 82 
independent clinical studies. Most ongoing studies are being conducted either during 
or following adjuvant therapy in women with breast cancer, with exercise 
interventions following standard exercise prescription guidelines consisting of 
moderate exercise training three days per week. But many of the studies were poorly 
designed. Several randomized trials in this field have compared an exercise 
intervention with standard care. Some of them have a small sample size, do not 
measure with gold standard methods, and have relatively heterogeneous sub-groups 
of patients in terms of cancer type and current or prior anticancer therapy, which is of 
course dependent on the primary study question. The biggest limitation in the 
majority of these studies is that they did not adequately design the exercise 
prescription in accordance with the principles of exercise training, nor did they 
adequately report the components of the exercise prescription or adherence to the 
exercise prescription (K. L. Campbell, Neil, & Winters-Stone, 2012). 
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To understand the potential benefits of exercise-oncology research during 
cancer therapy, one must consider the adverse effects of cancer treatment. During 
the coping phase and at the beginning of the rehabilitation phase, the side effects of 
the cancer therapy play the most important role (see Figure 4). Adverse effects may 
be acute, resolving over a period of days, weeks, or months, or they may be 
persistent, lasting years after treatment is completed or even for the remainder of the 
patient’s life. Some adverse effects can begin during treatment and persist long after 
treatment has finished. There are five types of breast cancer therapy (Chemotherapy 
treatment, radiation, surgery, hormonal therapies, and targeted therapies). The 
therapy chosen is dependent on cancer type and size, and the age and fitness of the 
patient. The cancer treatment can have many side effects, directly or indirectly, on 
breast cancer patients’ fitness and quality of life (see Figure 5), where especially 
cancer related fatigue is the most reported side effect during and after treatment 
(Mustian et al., 2007). 
 
Figure 4. The Framework PEACE: an organizational model for examining physical exercise across the 
cancer experience (adapted from Courneya and Friedenreich 2001). Contribution of my thesis is 
labeled with red areas. 
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Figure 5. A biobehavioral model for the study of exercise interventions for cancer-related fatigue 
(adapted from Al-Majid and Gray, 2009) 
Some of the acute and persistent effects of cancer treatments can be 
positively influenced by physical exercise. It has positive effects on the 
cardiovascular, musculoskeletal, nervous, endocrine, and immune systems and 
additionally, a number of beneficial factors like body composition, body weight, 
cancer related fatigue, pain, sleep disturbance, and positive influence on the 
symptoms of lymphedema have already been shown in cancer patients (Baumann et 
al., 2013). Exercise training and physical activity also have a positive psychosocial 
effect, which can decrease adverse effects, such as depression, anxiety, low self-
esteem, and the psychological components of cancer-related fatigue. Here, most 
studies of cancer survivors analyzed the effect of aerobic exercise training, some a 
combination of aerobic exercise and resistance training (Mishra et al., 2012). A 
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minority of them performed resistance training (Strasser, Steindorf, Wiskemann, & 
Ulrich, 2013). 
 
1.3. Exercise & breast cancer research overview 
In first decades of research in “exercise and breast cancer“ the main 
knowledge was provided by observational epidemiological studies. One of the 
leading research group was around C. M. Friedenreich, who also reviewed the 
association between physical activity and breast cancer risk in studies of the last 
three decades (Lynch, Neilson, & Friedenreich, 2011). They found that physical 
activity is associated with decreased breast cancer risk via multiple interrelated 
biologic pathways that may involve adiposity, sex hormones, insulin resistance, 
adipokines, and chronic inflammation. The evidence of observational studies was 
important, but since the year around 2000 it was argued that for additional progress 
to be made in this field, there need to be a bigger focus on intervention studies of 
physical activity and breast cancer (Friedenreich, 2001). The limitations of 
observational studies include crude and incomplete exercise supervision and 
assessment, lack of consideration of the underlying biological mechanisms that are 
operative, as well as a lack of adequate control for confounding and effect 
modification. 
A recent review of Battaglini et al. (2014) describes the development of 
research in the field of breast cancer and exercise training from its beginnings in the 
year 1989. Twenty-five years ago, intervention trials started to examine the role of 
exercise in breast cancer patients and survivors. Early studies (MacVicar, 
Winningham, & Nickel, 1989; Mock et al., 1994; Mock et al., 1997; Schwartz, 1999; 
Winningham, MacVicar, Bondoc, Anderson, & Minton, 1989) were conducted with 
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breast cancer patients during adjuvant therapy. Most of them were home-based 
intervention trials that analyzed the effect of aerobic training. The major modes of 
aerobic exercise included walking, swimming, and cycling. 
Since the year 2000, more studies have been designed which met the criteria 
of randomized controlled trials, and the outcomes during cancer therapy were more 
focused (A. Campbell, Mutrie, White, McGuire, & Kearney, 2005; Cheema & Gaul, 
2006; Courneya et al., 2003; Herrero et al., 2006; Hutnick et al., 2005; Kim, Kang, 
Smith, & Landers, 2006; Kolden et al., 2002; Pinto, Frierson, Rabin, Trunzo, & 
Marcus, 2005; Schwartz, 2000; Segal et al., 2001; Turner, Hayes, & Reul-Hirche, 
2004). Over the following years, study design shifted to focus on a combination of 
aerobic and resistance training. But in the first two decades of exercise oncology 
research, no study was designed that focused exclusively on resistance training. The 
first studies that used resistance exercise training as the main mode of exercise were 
performed after 2007. From that time on, more supervised studies were performed. 
For studies that used resistance training, weight machines, free weights, elastic 
bands, tubing, therapeutic balls, and resistance-training circuits were used. In most 
studies, weight machines were applied, and the resistance training consisted of 
exercises for all major muscle groups. Exercises to strengthen the upper body 
included bench press (pectoralis), chest cross (horizontal flexion of the shoulder 
joint), shoulder press (trapezius), pull downs (latissimus dorsi), biceps curls, triceps 
extensions, and exercises for the abdominal muscles (sit-ups). Lower body exercises 
included the leg press (quadriceps femoris). There is as yet a limited number of 
studies evaluating the efficacy of resistance training. I am aware of 11 RCT studies 
that use resistance training alone or as part of the study design (Ahmed, Thomas, 
Yee, & Schmitz, 2006; C. Battaglini et al., 2007; Cormie et al., 2013; Courneya et al., 
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2007; Musanti, 2012; Schmitz, Ahmed, Hannan, & Yee, 2005; Schmitz, Ahmed, et 
al., 2010; Schwartz & Winters-Stone, 2009; Schwartz, Winters-Stone, & Gallucci, 
2007; Winters-Stone et al., 2012; Winters-Stone et al., 2011a; Winters-Stone et al., 
2013), aside from the BEST- (Potthoff et al., 2013) and BEATE-Studies (Schmidt, 
Wiskemann, et al., 2013). The average frequency of training was 3 days per week, 
ranging from 2-5 training sessions per week, with an overall training duration average 
of 23 weeks (in a range of 3-48 weeks). Each training session lasted 46 min on 
average, with training sessions ranging from 15-90 min. In those studies also 
applying aerobic training the intensity varied from 40%-85% of maximum heart rate, 
40%-90% of VO2peak, while the intensity for resistance training ranged from 55%-85% 
of 1RM. The most commonly evaluated variables in breast cancer and exercise 
studies were cardiorespiratory function, body composition, muscular strength, 
depression, overall quality of life, and (cancer-related) fatigue. Follow up studies 
several years after an intervention and survival data is rare. A first follow up 
investigation by Courneya et al. (2014) supports the findings of the observational 
studies that physical activity after a breast cancer diagnosis is associated with 
improved cancer outcomes. 
Overall the exercise training in studies of the past 25 years appears to be safe 
for most breast cancer patients and improvements in physiological, psychological, 
and functional parameters can be attained with regular participation in moderate 
intensity exercise. Regarding efficacy a significant improvement in cardiorespiratory 
function was observed for the exercise group, when using estimated measurements 
derived from a submaximal treadmill testing protocol or directly using a cycle 
ergometer. Significant decrease in meters walked during a 6 min and 2 km walk tests 
was observed in the control group while improvements in a 12 min walk test 
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approached significance in the exercise group (C. L. Battaglini et al., 2014). To detect 
the cardiorespiratory fitness outcome of breast cancer survivors the estimated and/or 
submaximal treadmill VO2peak or 12-min walk test were used in most of the studies. 
Regarding a quick overview about the endurance performance the 12-min walk test is 
enough. But in order to be able to describe the cardiorespiratory fitness more 
precisely there are important disadvantages of the treadmill tests with patients. First 
of all patients have to get used to walk or run on a treadmill, before testing. The 
second point is that there is a bias of patient selection. Patients, whose fitness is bad, 
are physically not able to perform the test on a treadmill. And finally the estimation of 
VO2peak after submaximal test is not valid enough for breast cancer patients, because 
the VO2peak data is based on calculations out of healthy individuals. 
Therefore, we used the cardiorespiratory fitness test on a bicycle to solve the 
mentioned difficulties in the I. Publication (Klassen et al., 2014). With one of the 
biggest study population (N=222) in this research field we were able to measure with 
gold standard method the cardiorespiratory fitness of breast cancer patients during 
adjuvant treatment. 
This review also reports that in the exercise group also positive body 
composition changes were observed, with the most notorious changes in significant 
decrease in body fat and increase in lean body mass, whereas control group 
experience significant increases in body fat and a trend toward an increase in overall 
body mass. There is also a clear trend towards greater improvement in quality of life, 
reduction in (cancer-related) fatigue and depression in the exercise group when 
compared to the control group. 
Unfortunately, very limited and no definite conclusion could be drawn until now 
regarding the effects of resistance training programs as the main mode of exercise 
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training (Cormie et al., 2013; Winters-Stone et al., 2012; Winters-Stone et al., 2011b; 
Winters-Stone et al., 2013) and those that used resistance training as an arm part of 
the study design (Courneya et al., 2007; Musanti, 2012; Schwartz et al., 2007). 
Regarding the effects of resistance training on changes in body composition, a 
significant increase in body mass and lean body mass was observed in the exercise 
group. Upper body strength significantly increased in the exercise group while for 
lower body, strength significantly increased in both, exercise and control groups with 
a greater increase observed in the exercise group. No significant changes in quality 
of life were observed in either the exercise and control groups. Very limited and no 
definite conclusion can be drawn at this time regarding the effects of resistance 
training on fatigue, depression, and overall quality of life in breast cancer patients. 
This is why we did the research in this area with better design quality 
(controlling for many variables that can confound study results such as type, 
frequency, intensity of exercise, different types of cancer treatments, age of patients, 
previous fitness levels, and other co-morbidities that can further diminish the 
tolerability for exercise participation and large samples sizes) to be able to do more 
precise exercise guidelines (Potthoff et al., 2013). 
Furthermore, muscle function in these studies is mostly measured in a 
pragmatic way with commonly estimated one repetition maximum strength test (1-
RM) (Strasser et al., 2013). The advantage is that it can be carried out for most 
muscle groups, but the limitation is a strong risk of praxis adaption. The most precise 
form to measure the strength is with an isokinetic device, but it is expensive and 
needs an expert to handle with this device (Christensen et al., 2014). In our BEST 
and BEATE study we were able to use this gold standard strength testing procedure 
and we reported this strength results in both studies at the baseline of the recruitment 
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(II. Publication) and summarized them in the IV publication (Steindorf et al., 2014) 
after completion of the intervention in the BEST study. 
Furthermore in breast cancer research there is a lack of knowledge about the 
training prescriptions and the intensity. The roundtable of the American College of 
Sports Medicine (Schmitz, Courneya, et al., 2010) recommend the 150 min/wk with 
moderate or 75 min/wk with vigorous intensity for endurance and/or resistance 
training, taking into account the individual possibility for cancer patients. But no one 
investigated the moderate or vigorous intensity for breast cancer patients during 
adjuvant therapy adequately. Consequently, it is unknown which objective measured 
intensity needs to be recommend for breast cancer patients. The ACSM’s guidelines 
for exercise prescription in healthy adults offers intensity classifications in 
percentages of oxygen uptake reserve (%VO2R), heart rate reserve (%HRR), 
maximal oxygen uptake (%VO2max), and maximal heart rate (%HRmax). Therefore, we 
used these parameters to investigate whether the ACSM’s exercise intensity 
classification is valid for breast cancer survivors (III. Publication) (Scharhag-
Rosenberger et al., 2015). 
Cancer related fatigue, as one of the most debilitating multidimensional 
symptoms was not completely understood yet. Many breast cancer patients receive 
radiotherapy. During and after radiotherapy breast cancer patients often suffer from 
cancer-related fatigue which frequently impairs quality of life (QoL) (Lee et al., 2008; 
Noal et al., 2011; Taunk et al., 2011). Physical activity for breast cancer patients has 
been reported to decrease fatigue, to improve emotional well-being and to increase 
physical strength. Our study adds to the current knowledge with respect to three 
understudied areas: (1) exercise was performed during radiotherapy; (2) the type of 
training was resistance exercise, and (3) the control group also received a group-
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based program so that physiological effects beyond psychosocial group-related 
effects were studied. Our aim was to assess the effects of a 12-week supervised 
resistance training on fatigue and physical fitness in breast cancer patients during 
adjuvant radiotherapy within a randomized controlled trial (BEST study). With my 
contribution the results are expected to enlarge more concrete exercise guidelines for 
breast cancer patients in the IV. Publication (Steindorf et al., 2014). Overall, with my 
contributions we addressed the aforementioned gaps in the framework PEACE, 
especially during breast cancer treatment. 
 
2. Background of the included data and work for the thesis 
The BEST study (clinicaltrials.gov: NCT01468766) is a randomized, controlled 
intervention trial investigating the effects of a 12-week supervised progressive 
resistance training program in 160 patients with breast cancer undergoing adjuvant 
radiotherapy. BEST is an acronym derived from the German term „Bewegung und 
Entspannung für Brustkrebspatientinnen unter Strahlentherapie“. To exclude a 
possible group dynamic psycho-social bias, a group-based progressive muscle 
relaxation training (PMR) was offered at the same temporal extent (see Figure 6) as 
a control intervention. The BEST study has six assessment time points (T0-T5), 
beginning several weeks after surgery and ending with follow-up measurements after 
one year for each patient. The primary endpoint is cancer-related fatigue; secondary 
... -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... 38 ... 64Week
T0
Radiotherapy
Surgery T1 (End of radiotherapy) T2  (End of intervention)
Screening/
Informed 
Consent
T3
Arm 1: Resistance training   2 x 1h / week
Arm 2: Relaxation training 2 x 1h / week
Randomisation T4 T5
Figure 6. Design of the BEST-study 
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endpoints include cardiorespiratory fitness and isokinetic versus isometric 
performance. Additionally, immunological and inflammatory parameters, quality of life 
(QoL), depression, and cognitive capacity were analyzed. Biomarkers located in 
serum, plasma, PBMCs, urine and saliva have been collected and Tregs have been 
analyzed (week 0, 7, 13). Cardiopulmonary exercise tests and comprehensive 
strength measures (IsoMed2000), as well as bioelectrical impedance analysis (BIA), 
were performed pre- and post-intervention and at 6 and 12 months after. Additionally, 
comprehensive clinical, socio-demographic and lifestyle data has been collected. 
The recruitment goal of n=160 patients was successfully reached by March 
2013. Only four patients dropped out of the trial before the post-intervention 
assessment. Primary endpoint data is available in 95% of participants. The follow-up 
period ended in September 2014 with a participation rate of 90% six months post-
intervention, and an expected 82% after one year. These results contribute to a 
better understanding of the physiological and psychosocial effects and the biological 
mechanisms of resistance training and the impact of diverse cancer treatment 
regimes and types. The ultimate goal is the implementation of optimized intervention 
programs to reduce fatigue, improve quality of life, and potentially improve the 
prognosis. 
The second part of my data was from the patients enrolled in a second 
randomized controlled trial, the BEATE-study with the german acronym “Bewegung 
... -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... 26Week
T0 (Baseline) T1 (Intermediate) T2  (End of intervention)
Screening/
Informed
Consent
T3 (Follow-up)
Arm 1: Resistance training   2 x 1h / week
Arm 2: Relaxation training 2 x 1h / week
Randomization
Cycle 1 Cycle 2 Cycle  3 Cycle  4 Cycle  5 Cycle  6 Chemotherapy (regimen may vary)
Figure 7. Design of the BEATE-study 
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und Entspannung als Therapie gegen Erschöpfung” (ClinicalTrials.gov 
NCT01106820), which has a similar study design (Figure 7) and equal intervention 
form, but focuses on breast cancer patients under adjuvant chemotherapy with four 
assessment time points (T0-T3), with the last follow-up measurement after 6 months. 
More details of the study are presented elsewhere (Schmidt, Wiskemann, et al., 
2013). The safety of the resistance training during chemotherapy is monitored in the 
same way as in the BEST-study during radiotherapy. 
For comparisons 26 healthy women from with matched age range were 
recruited from Rhein-Neckar area, Germany for the INVEST study. This study name 
is an acronym for INVestigation of the Effects of Strength Training. The participants 
performed the same tests and resistance training program. 
As a study coordinator and doctoral candidate, I was responsible for the BEST 
study for three years and managed most of the organizational aspects of the trial. 
Furthermore, I recruited most of the patients with the help of the oncologists and did 
most of the physical performance assessments (about 700 cardiopulmonary exercise 
tests and 700 isokinetic strength tests, including BEATE and INVEST study). Clinical 
assessments like bioelectrical impedance analysis, waist-to-hip-ratio measuring, trial 
making tests, and anthropometrical measurements were also a part of my work. 
Regular phone calls for appointments and motivational aspects were needed to 
complete the intervention and assessments of the patients in order to get the best 
possible adherence rate. My responsibility included the distribution and mailing of the 
Fatigue Assessment Questionnaire (FAQ) and questionnaire of the European 
Organization for Research and Treatment of Cancer (EORTC QLQ-C30). I was also 
involved in the development and implementation of new study-related standard 
operating procedures of the group “Physical Activity and Cancer”. 
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Two peer-reviewed publications authored by me, and two which I co-authored, 
have been submitted or already accepted. For the co-authored articles, beyond 
patient recruitments in the BEST study and my data collection, I supported the first 
authors with my ideas, data cleansing to establish a uniform and improved data 
quality, and/or verified the regression analysis and created graphs and wrote 
comments for the manuscripts. 
 
2.1. Aim and objectives of the thesis 
The main objective of the studies presented in this thesis is to provide further 
insight into the impact of breast cancer during therapy on cancer related fatigue, 
physical fitness, benefits of resistance exercise during cancer treatment and how 
exercise prescriptions can be adapted for breast cancer patients. To meet this aim 
the first publication describes the cardiorespiratory fitness in breast cancer patients at 
different time points of anti-cancer treatment. The second publication investigates the 
muscle strength in breast cancer patients in different adjuvant treatment settings and 
compares it with data from healthy individuals. The third publication investigated 
whether and how intensity prescriptions for healthy adults by guidelines of the 
American College of Sports Medicine need to be adapted for breast cancer survivors. 
The fourth publication evaluates the efficacy of the randomized controlled trial of 
resistance training beyond the psychosocial benefits associated with group-based 
relaxation intervention on cancer-related fatigue and quality of life in breast cancer 
patients receiving adjuvant radiotherapy. After the manuscripts the studies and 
results are discussed. 
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2.1.1. Main research questions 
 How is the cardiorespiratory fitness affected in breast cancer patients at 
different time points of cancer treatment? (I. Publication) 
 How is the muscular strength affected in breast cancer patients during cancer 
treatment? (II. Publication) 
 Does moderate and vigorous intensity aerobic exercise prescription of the 
American College of Sports Medicine guidelines fit for patients after breast 
cancer treatment? (III. Publication) 
 Is the 12-week resistance training more effective on cancer related fatigue 
beyond possible psychosocial effects of a group-based intervention among 
breast cancer patients during adjuvant radiotherapy? (IV. Publication) 
 
2.1.2. Secondary questions 
 Are the physical fitness tests (I. & II. Publication) and progressive resistance 
training during radiotherapy safe and are they feasible for breast cancer 
patients (III. & IV. Publication)? 
 Which factors might be responsible for the cardiorespiratory fitness and 
muscular strength breast cancer patients undergoing cancer therapy? (I. & II. 
Publication)? 
 Is resistance training more beneficial for quality of life, depression, cognitive 
function, and early radiotoxicity, as well as on physical fitness, including 
muscle strength, cardiorespiratory fitness and flexibility? (IV. Publication) 
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2.2. Interrelation and the context for my research framework 
For my thesis, data from two randomized controlled clinical exercise 
intervention trials and from a healthy control trial with resistance training intervention 
were used: the BEST, BEATE (ClinicalTrials.gov ID NCT01468766 and 
NCT01106820) and INVEST study. The high quality of the study designs, the use of 
gold standard measurement methods and identical surveys helped to get a better 
validity and reliability for my publication. The following four publications address 
questions about the impact of exercise therapy and physical fitness in breast cancer 
patients during or shortly after completion of different cancer treatments. In the first 
two publications, muscular function and cardiorespiratory fitness were investigated to 
understand the impact of cancer treatment on fitness and how clinically relevant 
breast cancer patient groups differ from each other. This data was compared with 
healthy individuals to determine their physical limitations. These results imply an 
analysis, presented in the third publication, which evaluated the required adaptations 
for endurance training intensity prescription in breast cancer patients immediately 
after cancer treatment, taking the American College of Sports Medicine’s exercise 
guidelines into account. These guidelines must be proved, because their intensity 
recommendations for breast cancer patients are based on data for healthy 
individuals. The last article raised the question of how cancer-related fatigue can be 
improved beyond the psychosocial group effects, which was a lack in previous 
studies. Therefore a randomized controlled trial with progressive resistance training 
vs. relaxation training (control group) was analyzed in order to provide a non-biased 
effect of the resistance training. All of the studies presented aim to give physicians, 
sport scientists, and all other therapists involved the ability to inform their patients 
about the importance of fitness status and the benefits of exercise therapy during 
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cancer treatment. Furthermore, the purpose of my thesis is to provide more 
knowledge for an optimal exercise therapy as an integral part of cancer treatment for 
breast cancer patients. 
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Abstract 
Purpose 
The aim of this work was to investigate cardiorespiratory fitness in breast cancer 
patients at different time points of anti-cancer treatment. 
Patients and Methods 
Non-metastatic breast cancer patients (n=222, mean age 55 years) were categorized 
into four subgroups according to their treatment status. Cardiopulmonary exercise 
testing (CPET) was used to measure patients’ cardiorespiratory fitness, including 
oxygen delivery and metabolic muscle function. Testing was performed by bicycle 
ergometry, and maximal oxygen uptake (VO2peak) was measured. Heart rate during 
exercise at 50 watts (HR50) was assessed as a cardiocirculatory parameter and 
ventilatory threshold (VT) was used as an indicator of the O2 supply to muscle. 
Analysis of covariance was used to estimate the impact of different cancer treatments 
on cardiorespiratory fitness with adjustment for clinical factors. 
Results 
Submaximal measures were successfully assessed in 220 (99%) and 200 (90%) 
patients for HR50 and VT, while criteria for maximal exercise testing were met by 176 
patients (79%), respectively. The mean VO2peak was 20.6±6.7 ml/kg/min, mean VT 
10.7±2.9 ml/min/kg and mean HR50 112±16 beats/min. Chemotherapy was 
significantly associated with decreased VO2peak, with significantly lower adjusted 
mean VO2peak among patients post adjuvant chemotherapy compared to patients with 
no chemotherapy or those who just started chemotherapy regime (all p<0.01). 
Patients post adjuvant chemotherapy reached only 63% of the VO2peak level expected 
for their age- and BMI-category (mean VO2peak 15.5±4.8 ml/kg/min). Similarly, HR50 
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was significantly associated with treatment. However, VT was not associated with 
treatment. 
Conclusion 
Breast cancer patients have marked and significantly impaired cardiopulmonary 
function during and after chemotherapy. Hereby, chemotherapy appears to impair 
cardiorespiratory fitness by influencing the oxygen delivery system rather than 
impacting metabolic muscle function. Our findings underline the need of exercise 
training in breast cancer patients to counteract the loss of cardiorespiratory fitness 
during the anti-cancer treatment. 
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Background 
Breast cancer–specific survival has substantially improved over the past 
decades. In the United States, the relative survival rate is about 89% at 5 years after 
breast cancer diagnosis (Howlader et al., 2011). Nevertheless, there are concerns 
about morbidity and mortality, particularly related to cardiovascular fitness. To date, 
cardiovascular disease mortality is more common among breast cancer survivors 
than breast cancer-related mortality among women who were 66 years or older 
(Patnaik, Byers, DiGuiseppi, Dabelea, & Denberg, 2011). An important predictor of 
cardiovascular events and all-cause mortality is cardiorespiratory fitness, as shown in 
healthy individuals and clinical populations including breast cancer patients after anti-
cancer treatment (Blair et al., 1996; Peel et al., 2009). Poor cardiorespiratory fitness 
also has direct consequences on the performance of everyday tasks and thus 
impacts quality of life. 
The gold standard of measuring cardiorespiratory fitness is cardiopulmonary 
exercise testing (CPET) (American Thoracic & American College of Chest, 2003). 
This method determines the overall cardiovascular and respiratory function during 
exercise, yielding the peak oxygen uptake (VO2peak) as a maximal performance 
measure. In cancer patients, the oxygen system can be adversely affected by 
chemotherapy. Effects of chemotherapeutic agents on the respiratory, cardiac, blood, 
vascular, or skeletal muscle functions have been observed or hypothesized, 
potentially contributing to the impairment of cardiorespiratory fitness (Lakoski, Eves, 
Douglas, & Jones, 2012). Cardiorespiratory function is not routinely measured at any 
stage of breast cancer treatment, and CPET is scarcely used in clinical settings (L. 
W. Jones, Eves, Haykowsky, Joy, & Douglas, 2008). Although low VO2peak measures 
have been observed in intervention studies across the breast cancer survivorship 
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continuum (Bourke et al., 2013), to our knowledge, there is very limited information 
on the impact of cancer therapy on cardiorespiratory fitness using gold standard 
testing methods. 
Therefore, this study investigated maximal and submaximal cardiorespiratory 
fitness parameters among 222 non-metastatic breast cancer patients at the 
beginning of chemotherapy, after completion of chemotherapy, or without 
chemotherapy, using the gold standard for cardiorespiratory measurement. We 
compared cardiorespiratory capacity of these patient groups adjusted for clinical 
relevant parameters and compared them to healthy women with the same age and 
BMI. The role of cancer therapy was investigated.  
 
Patients and Methods 
Setting and Participants 
The data for this analysis were data at enrollment into two randomized 
controlled exercise trials (baseline testing), the BEATE-Study and the BEST-Study 
(Potthoff et al., 2013; Schmidt et al., 2013). The studies investigated the effects of a 
12 week progressive resistance vs. relaxation training in breast cancer patients 
undergoing chemotherapy (BEATE-Study) or radiotherapy (BEST-Study). Besides 
the different treatment modalities, the inclusion/exclusion criteria were equal in both 
studies. Exact inclusion and exclusion criteria and more details of the trials are 
presented elsewhere (Potthoff et al., 2013; Schmidt et al., 2013). Included in this 
analysis were all participants who had completed the baseline assessment by 
November 2012 (n=222). Both trials were conducted with parallel designs at the 
National Center for Tumor Diseases (NCT) in Heidelberg, Germany. The University 
of Heidelberg Ethics Committee has approved both trials and written informed 
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consent was obtained for all procedures. Women with histologically confirmed stage 
0-III primary breast cancer after lumpectomy or mastectomy were eligible for the 
study. Participants recruited in the BEST-Study had the baseline CPET within 14 
days before start of radiotherapy. Of these participants, a majority had not received 
chemotherapy (n=87), while some had received chemotherapy in the adjuvant (n=25) 
or neo-adjuvant (n=23) chemotherapy setting. Patients enrolled in the BEATE-Study 
(n=87) performed baseline CPET at the end of the first or second chemotherapy 
cycle. Based on the different treatment histories, four subgroups (see Figure 1) could 
be identified and were analyzed: (1) no chemotherapy, (2) started adjuvant 
chemotherapy, (3) post neo-adjuvant chemotherapy, (4) post adjuvant 
chemotherapy. 
 
Figure 1: Stratification of study population with respect to breast cancer treatment at time point of 
cardiopulmonary exercise testing (CPET) 
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Cardiorespiratory Fitness 
CPET was performed using an electronically braked cycle ergometer 
(ergoselect 100, ergoline, Bitz, Germany). A stepwise incremental exercise protocol 
was applied starting at 50 watts with increments of 25 watts every two minutes until 
volitional exhaustion or medical reasons for exercise termination (see below) were 
reached. Gas exchange was measured using a breath-by-breath gas analysis system 
(ergostik, Geratherm Respiratory, Bad Kissingen, Germany) which was calibrated 
according to the instructions of the manufacturer before each test. To monitor patient 
safety, a 12-lead electrocardiogram (ECG) was applied (CardioPart 12 Blue, 
amedtec, Aue, Germany) and blood pressure was measured with a standard cuff 
sphygmomanometer at rest, in the middle of each exercise stage, and three times 
during the 5 min recover period. Exercise was terminated prematurely in the case of 
major ECG abnormalities, severe dyspnea or excessive RR increase (> 230 mmHg 
systolic and/or >110 mmHg diastolic). 
VO2peak values were included in the analyses that satisfied at least one of the 
following criteria for maximal effort was fulfilled: Respiratory Exchange Ratio (RER) 
>1.1 or Peak Heart Rate (HRpeak) ±10% beats of the age-appropriate reference value 
(Howley, Bassett, & Welch, 1995; Midgley, McNaughton, Polman, & Marchant, 2007). 
VO2peak values were considered in relation to body weight (ml/min/kg). In addition, 
absolute values (ml/min) were also given. Peak work rate, defined by the maximal 
power output (in watt) reached at the end of the highest exercise level, was 
interpolated if the last exercise stage was not maintained for 2 min. Peak oxygen 
uptake (VO2peak) and peak respiratory exchange ratio (RERpeak) were assessed as 
the highest 30 second average during exercise. 
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Submaximal exercise measures during CPET included the ventilatory 
threshold (VT) and heart rate at 50 watts (HR50). The VT was determined using the 
V-slope method according to Beaver et al. (Beaver, Wasserman, & Whipp, 1986) as 
primary criterion and the first rise in the ventilatory equivalent for oxygen (VE/VO2) as 
a secondary criterion (Meyer, Lucia, Earnest, & Kindermann, 2005). VT was rated 
independently by two experienced investigators; in case of different results, the raters 
re-evaluated the threshold together. The VT was also independently rated as “easily 
determinable”, “difficult to determine” or “indeterminable”. In the latter case, VT was 
not included in the analysis. In the analyses, VT values were considered relative to 
body weight (ml/min/kg). Resting HR and HR50 were obtained from the ECG 
recordings as 5 second averages in a sitting position before the start of exercise and 
at the end of the 50 watt stage, respectively. 
 
Medical and patient demographics 
Medical characteristics and treatment modalities were abstracted from medical 
records. Overall performance status was determined by the attending oncologist 
using the ECOG (Eastern Cooperative Oncology Group) performance score system 
at the time of enrollment. Weight and height were measured at baseline. Exercise 
behavior in the year before breast cancer diagnosis was assessed through self-
developed surveys abstracted from the International Physical Activity Questionnaire. 
Participants were asked about the type, frequency, and duration of exercise (e.g. 
walking, cycling, and intentional exercise). Furthermore, exercise behavior during 
adolescence was also recorded classified as “competitive exercise” (for at least 3 
years), “non-competitive exercise”, or “none”. 
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Statistical Analysis 
Clinical and patient demographics, as well as fitness parameters were 
investigated by descriptive analyses for the entire study population, and also stratified 
by the four treatment subgroups. Between-group differences were assessed using χ2 
or Fisher’s exact test for categorical variables, and using one-way ANOVA for 
continuous variables. Expected VO2peak values were calculated for each woman from 
the regression formula presented by Koch et al. (Koch et al., 2009), according to her 
BMI (<25, ≥25 kg/m2) and age (in 5-year categories). Differences between the 
measured and the expected VO2peak values were investigated using paired t-tests. 
For each patient, the proportion of the observed versus expected VO2peak values was 
calculated. 
Analyses of covariance (ANCOVA) models were used to test different fitness 
outcomes (i.e. VO2peak, VT, and HR50) with the categorical treatment variable (no 
chemotherapy / started chemotherapy / post neo-adjuvant chemotherapy / post 
adjuvant chemotherapy) as independent exposure of interest. The assumptions of 
homoscedasticity, normality of the residuals, and homogeneity of regression slopes 
were not violated. The models were adjusted for covariates selected on the basis of 
the theory of directed acyclic graphs (Textor, Hardt, & Knuppel, 2011), i.e. age at 
diagnosis, pre-diagnosis BMI (17 to <25, 25 to <30,  30 kg/m2), smoking status at 
diagnosis (current, former, never), sports in the year before diagnosis (none, >0-15 
MET*h/wk, >15-35 MET*h/wk, >35 MET*h/wk), sports during adolescence (none, 
non-competitive, competitive), walking (0-1 5h/wk, >1-3 5h/wk, >3-5 5h/wk, >5h/wk) 
and cycling (none, >0-1 h/wk, >1-3 h/wk, >3 h/wk) in the year before diagnosis, use 
of beta-blockers, or pre-existing cardiac diseases. Sensitivity analyses were 
performed by including hemoglobin level, trastuzumab treatment, hormone treatment, 
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or type of chemotherapy (taxanes, anthracyclines), where the causal direction of the 
association with cardiopulmonary fitness is unclear. We also checked the 
parsimonious models including only significant covariates and those that changed the 
treatment estimate by >10%, but there were no substantial changes in the results. In 
addition, type of chemotherapeutic agent was further evaluated among patients who 
have started chemotherapy using a model that included categorized the variable as 
taxane use only, anthracycline use only, or use of both. 
 
Results 
A total of 222 breast cancer patients with a mean age of 54.8±9.3 years were 
included in the analyses. Characteristics of the population are presented in Table 1. 
Patients who received no chemotherapy were slightly older than those in the other 
treatment groups. Mean hemoglobin (Hb) values were within the normal range, of 
above 12 g/dl, with the exception of the group post adjuvant chemotherapy, where 
the mean Hb was 11.4 g/dl indicating NCI-grade 1 anemia. Overall, only 2 patients 
had a Hb value slightly below 10 g/dl, which is defined as NCI-grade 2 anemia.
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TABLE 1: Characteristics of the study population 
 
 TOTAL No CT Started CT Post neo. CT Post adj. CT 
 
p* 
TOTAL n,%  222 100% 87 100% 87 100% 23 100% 25 100%  
  
Age [years], mean (SD)  54.8 (9.3) 57.3 (8.7) 53.5 (9.6) 51.8 (10.0) 53.5 (7.7) 0.011 
  
Weight [kg], mean (SD)  71.7 (14.1) 73.1 (14.2) 69.6 (12.7) 70.9 (11.4) 74.6 (19.5) 0.28 
  
Height [cm], mean (SD)  165.5 (6.6) 164.7 (7.1) 165.8 (6.5) 165.7 (4.9) 167.4 (6.4) 0.29 
  
BMI at baseline, mean (SD)  26.2 (4.9) 27.0 (5.2) 25.3 (4.4) 25.9 (4.5) 26.5 (5.9) 0.16 
  
Hemoglobin [g/dl], mean (SD)  12.8 (1.2) 13.5 (0.9) 12.3 (1.1) 12.8 (0.9) 11.4 (1.0) <.0001 
  
Resting HR, mean (SD)  82.6 (14.5) 77.9 (12.8) 85.3 (14.2) 80.8 (10.3) 91.6 (18.3) <.0001 
  
Days since surgery, mean (SD)  66.6 (51.2) 44.2 (13.0) 58.9 (29.1) 59.2 (55.5) 177.8 (51.8) <.0001 
  
Days since CT end, mean (SD)  54.8 (49.1) n.a.  n.a.  80.2 (55.5) 27.1 (15.9) 0.0001 
  
Stage, n (%) 0  15 6.8% 12 13.8% 1 1.1% 2 8.7% 0 0.0% <.0001 
1  101 45.5% 57 65.5% 29 33.3% 8 34.8% 7 28.0%  
2  80 36.0% 18 20.7% 43 49.4% 9 39.1% 10 40.0%  
3  26 11.7%   14 16.1% 4 17.4% 8 32.0%  
             
ECOG, n (%) 0  190 85.6% 77 88.5% 74 85.1% 19 82.6% 20 80.0% 0.21 
1  24 10.8% 8 9.2% 7 8.0% 4 17.4% 5 20.0%  
2  1 0.5% 1 1.1% 0 0.0% 0 0.0% 0 0.0%  
missing  7 3.2% 1 1.1% 6 6.9% 0 0.0% 0 0.0%  
  
Taxane therapy, n (%)  82 36.9% n.a.  34 39.1% 23 100.0% 25 100.0% <.0001 
  
Anthracycline therapy, n (%)  119 53.6% n.a.  74 85.1% 22 95.7% 23 92.0% 0.43 
  
Herceptin therapy, n (%)  28 12.6% n.a.  19 21.8% 4 17.4% 5 20.0% 0.89 
  
Hormone therapy, n (%)  65 29.3% 47 54.0% 0 0.0% 8 34.8% 10 40.0% <.0001 
             
Beta-blocker use, n (%)  35 15.8% 15 17.2% 10 11.5% 4 17.4% 6 24.0% 0.45 
  
Smoking before diagnosis, n (%)  38 17.1% 16 18.4% 16 18.4% 5 21.7% 1 4.0% 0.31 
             
Walking before diagnosis, n(%) 
0-1 h/wk 
  
46 
 
20.7% 
 
14 
 
16.1% 
 
24 
 
27.6% 
 
5 
 
21.7% 
 
3 
 
12.0% 
0.052 
>1-3 h/wk  70 31.5% 26 29.9% 25 28.7% 10 43.5% 9 36.0%  
>3-5 h/wk  46 20.7% 14 16.1% 25 28.7% 3 13.0% 4 16.0%  
>5h/wk  47 21.2% 27 31.0% 10 11.5% 4 17.4% 6 24.0%  
missing  13 5.9% 6 6.9% 3 3.4% 1 4.3% 3 12.0%  
 
Cycling before diagnosis, n(%) 
none 
  
77 
 
34.7% 
 
33 
 
37.9% 
 
25 
 
28.7% 
 
10 
 
43.5% 
 
9 
 
36.0% 
0.26 
>0-1 h/wk  76 34.2% 26 29.9% 32 36.8% 7 30.4% 11 44.0%  
>1-3 h/wk  42 18.9% 17 19.5% 18 20.7% 6 26.1% 1 4.0%  
>3h/wk  19 8.6% 8 9.2% 10 11.5% 0 0.0% 1 4.0%  
missing  8 3.6% 3 3.4% 2 2.3% 0 0.0% 3 12.0%  
  
Sports before diagnosis, n (%)            0.048 
none  75 33.8% 38 43.7% 19 21.8% 11 47.8% 7 28.0%  
>0-9 MET*h/wk  53 23.9% 23 26.4% 19 21.8% 5 21.7% 6 24.0%  
>9-21 MET*h/wk  45 20.3% 13 14.9% 25 28.7% 4 17.4% 3 12.0%  
>21 MET*h/wk  43 19.4% 12 13.8% 21 24.1% 3 13.0% 7 28.0%  
missing  6 2.7% 1 1.1% 3 3.4% 0 0.0% 2 8.0%  
  
Sports in adolescence, n (%)            0.078 
no sports  83 37.4% 35 40.2% 29 33.3% 8 34.8% 11 44.0%  
non-competitive  87 39.2% 41 47.1% 30 34.5% 10 43.5% 6 24.0%  
competitive   47 21.2% 10 11.5% 26 29.9% 5 21.7% 6 24.0%  
missing  5 2.3% 1 1.1% 2 2.3%   2 8.0%  
Abbreviations: BMI, body mass index; HR, heart rate; CT, chemotherapy; ECOG, Eastern Cooperative Oncology Group (performance status); 
MET, metabolic equivalent; SD, standard deviation. 
* One-way ANOVA for continuous variables, Chi2 or Fisher’s exact test for categorical variables. 
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The mean duration of exercising in the CPET was 6 min 53 s, which is valid to 
determine the VO2peak (Midgley, Bentley, Luttikholt, McNaughton, & Millet, 2008). Of 
the sample population, 176 patients (79.3%) exercised until exhaustion and fulfilled 
the criteria for maximal effort, therefore were included in the analysis of maximal 
exercise measures. On the other hand, 46 patients (20.7%) did not fulfill the criteria 
for maximal effort. In 18 cases (8.1%), exercise was terminated prematurely for 
medical reasons: 7 patients (3.2%) demonstrated an excessive increase in blood 
pressure, 3 patients (1.4%) demonstrated new ECG abnormalities, 1 (0.5%) patient 
experienced severe dyspnea, and 7 patients (3.2%) experienced orthopedic 
problems, such as knee or back pain. However, no major adverse event occurred. An 
additional 28 patients (12.6%) reported problems with the face mask, had poor 
compliance or experienced other volitional reasons to terminate the CPET before 
exhaustion was reached. VT was indeterminable in 22 out of 222 cases (9.9%) as a 
result of high/low ventilation or due to above mentioned medical abort criteria. In 109 
cases (49.1%), VT was easily determinable, while 91 (41.0%) were deemed difficult 
to determine. 
The peak and submaximal exercise measures are summarized in Table 2. The 
mean VO2peak was lowest among patients post adjuvant chemotherapy (15.5±4.8 
ml/min/kg) and highest among patients who had just started chemotherapy (23±7.1 
ml/min/kg). The VT was also highest among patients who had just started 
chemotherapy (11.4±3.4 ml/min/kg), but did not differ substantially between the other 
three groups (p=0.21). 
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The mean HR50 was highest among those post adjuvant chemotherapy with a tendency of tachycardia in this group (see Table 
1) and lowest in the group without chemotherapy. The biggest increases from resting HR to HR50 were observed among patients in 
post neo-adjuvant and adjuvant chemotherapy groups. 
Table 2: Maximal (peak) and submaximal fitness parameters, mean (SD) 
 
  TOTAL No CT Started CT Post neo. CT Post adj. CT 
Peak fitness measures  n mean  (SD) mean  (SD) mean  (SD) mean  (SD) mean  (SD) 
  
VO2peak relative [ml/min/kg]  176 20.6 (6.7) 19.8 (5.4) 23.0 (7.1) 19.2 (6.8) 15.5 (4.8) 
  
VO2peak absolute [ml/min]  176 1416 (415) 1405 (374) 1544 (424) 1312 (353) 1076 (340) 
  
Peak work rate [W]  176 111 (28) 112 (27) 118 (27) 107 (24) 87 (24) 
  
Peak RER  176 1.18 (0.09) 1.15 (0.08) 1.17 (0.07) 1.22 (0.09) 1.23 (0.11) 
  
Peak HR [beats/min]  176 157 (18) 154 (16) 161 (17) 157 (22) 151 (20) 
  
Submaximal fitness measures 
  
VT relative [ml/min/kg]  200 10.7 (2.9) 10.3 (2.4) 11.4 (3.4) 10.3 (2.8) 10.0 (2.1) 
  
VT absolute [ml/min]  200 748 (163) 742 (145) 769 (196) 721 (137) 721 (115) 
  
HR at 50 watts [beats/min]  220 112 (16) 107 (13) 115 (15) 114 (16) 119 (19) 
Abbreviations: CT, chemotherapy; RER, respiratory exchange ratio; SD, standard deviation; VO2peak, peak oxygen consumption; VT, ventilatory threshold; HR, heart rate 
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Figure 2: Distribution of VO2peak, presented as percentage of expected values for healthy women with 
the same age and BMI. The boxes present the 1st and 3rd quartiles, the middle line the medians, and 
the Whisker-ends the 5th and 95th percentiles. 
 
The median VO2peak values in our patient population were significantly lower 
than the expected cardiorespiratory values according to the age- and BMI-related 
prediction formula (Koch et al., 2009) (Figure 2). Patients post adjuvant or neo-
adjuvant chemotherapy reached only a median of 63% or 75% of expected VO2peak, 
respectively. In contrast, patients who just started chemotherapy reached 96% of 
expected VO2peak. 
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Figure 3: Adjusted mean values of each treatment category regarding VO2peak, VT, and HR50. Least 
square means were calculated using analyses of covariance models adjusted for age, BMI, smoking 
before diagnosis, walking, cycling, and sports before diagnosis, sports during adolescence, use of 
beta-blocker, and pre-existing heart diseases. Differences between categories were tested using 
Tukey-Kramer tests and all statistically significant differences (p < 0.05) are indicated in the figures. 
In ANCOVA models 
the categorical treatment 
variable was significantly 
associated with VO2peak 
(p<.01, Figure 3), when 
adjusted for influencing 
factors such as age (p<.01), 
BMI (p<.01), cycling (p=.03), 
and smoking before 
diagnosis (p=.07). Hereby, 
the adjusted mean VO2peak 
among patients who had just 
started chemotherapy did not 
differ from those with no 
chemotherapy; however the 
adjusted means of those two 
groups were significantly 
higher compared to post 
adjuvant chemotherapy. The 
group which just started the 
chemotherapy and which had 
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no chemotherapy had a more favorable VO2peak compared to those who completed 
treatment. Notably, the VO2peak was even more reduced among those who finished 
adjuvant chemotherapy compared to those prescribed neo-adjuvant chemotherapy. 
There was no significant association between the type of anti-cancer treatment and 
VT in the final adjusted model. The only significant determinant of VT was BMI 
(p<.01). However, treatment was found to be borderline significant (p=.057) in the 
model without adjustment for walking, cycling, and sport activities, with highest VT 
values among those who had started chemotherapy (data not shown). 
In contrast, HR50 was significantly associated with treatment (p<.01) with 
significantly lower adjusted mean resting HR in patients with no chemotherapy 
compared to patients during or post adjuvant chemotherapy (p<.01). The only other 
covariate that showed a borderline significant association with HR50 in the adjusted 
model was use of beta-blockers (p=0.055) with lower HR among users. The adjusted 
models explained 46.1%, 31.8%, and 18.7% of the variance of VO2peak, VT, and 
HR50, respectively. 
Receipt of chemotherapy was also associated with decreased Hb-level, 
especially after completion of adjuvant chemotherapy (p<.0001). However, Hb-level 
showed no significant association with VO2peak, VT, or HR50, or any association 
between treatment regimes. These fitness measures did not alter when the models 
were adjusted additionally for Hb. Therefore, Hb was not a significant mediator of the 
effects of chemotherapy on cardiorespiratory fitness. 
Among patients who had just started adjuvant chemotherapy, 85% had 
received anthracyclines and only 39% had received taxanes. In contrast, nearly all 
patients post adjuvant or neo-adjuvant chemotherapy had received both, 
anthracyclines and taxanes, during the course of their chemotherapy (see Table 1). 
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Thus, the independent effects of those chemotherapeutic agents on VO2peak could not 
be determined. However, aforementioned treatment effect on VO2peak did not alter 
substantially when adjusting the model for taxane and anthracycline regimen. When 
investigating the subgroup of patients who had started adjuvant chemotherapy, the 
adjusted means of VO2peak were nearly identical for anthracycline use only, taxane 
use only, and combined therapy (data not shown). Similar results were found for the 
adjusted means of HR50. Adjustment for trastuzumab or hormone therapy was not 
found to alter the results. 
 
Discussion 
The present study of 222 non-metastatic breast cancer patients revealed 
alarmingly low cardiorespiratory fitness in breast cancer patients across the treatment 
continuum. The mean VO2peak among our sample population was 20.6±6.7 ml/min/kg, 
compared to the expected mean VO2peak of 24.3±5.5 ml/min/kg among healthy 
population of comparable age and BMI distribution (Koch et al., 2009). 
Cardiorespiratory fitness was significantly associated with type and stage of 
cancer treatment, with lower adjusted mean VO2peak among patients post adjuvant 
chemotherapy compared to patients with no chemotherapy or who had just started 
chemotherapy. On average, patients who had just started chemotherapy (i.e. had 
one or two cycles of chemotherapy) were capable of reaching 96% of the VO2peak 
level that is expected for their age- and BMI-category; however, among patients 
receiving post adjuvant chemotherapy (i.e. about 4 weeks after completion of 
chemotherapy), fitness levels were only 63% of the expected level. 
Cardiopulmonary Exercise Testing (CPETs) have been universally utilized in 
several randomized exercise trials (Bourke et al., 2013; L. W. Jones et al., 2012), 
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however, there have been few systematic investigations of effects of cancer therapy 
on cardiorespiratory fitness among breast cancer patients. To our knowledge, there 
has been only one study comparing VO2peak at various points of chemotherapy 
treatment and compared with the expected capacity in healthy women. Our study 
expands on previous methods by assessing submaximal exercise measures in 
addition to peak measures. This enabled analyses of patients who could not perform 
maximal exercise testing until exhaustion, which is a limitation of exercise testing in 
an oncology setting. 
The considerable reduction in VO2peak compared to healthy individuals is in 
accordance with the findings of Jones et al. (L. W. Jones et al., 2012). It therefore 
appears to be of good external validity, bur still needs confirmation in future studies. 
Jones and colleagues (2012) found that breast cancer patients during chemotherapy 
reached 73% of age-expected capacity of healthy sedentary women with a mean 
VO2peak of 17.4±4.3 ml/min/kg. This is consistent with our results, which revealed a 
mean VO2peak of 15.5±4.8 ml/kg/min about 4 weeks post adjuvant chemotherapy. 
Several intervention trials demonstrated VO2peak measures in breast cancer patients 
or survivors ranging between 18 to 26 ml/min/kg (Bourke et al., 2013). All published 
comparable studies that we know of, reported similar results to our findings 
(Courneya et al., 2007; Drouin, Armstrong, Krause, & Orr, 2005; L. W. Jones et al., 
2012; Kim, Kang, Smith, & Landers, 2006; Segal et al., 2001). In Jones et al. (L. W. 
Jones et al., 2012), marginally lower VO2peak values were described in partly 
metastatic breast cancer patients. Slightly higher values in other referenced studies 
(Courneya et al., 2007; Kim et al., 2006; Segal et al., 2001) might be attributable to a 
younger population; differences in the test method, namely higher VO2peak values, 
can be expected when using treadmill tests. The lower VO2peak values in Drouin et al. 
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(Drouin et al., 2005) can be explained due to recruitment of only sedentary 
population. However, these results lack adjustment for age, BMI or other potentially 
influencing factors, and had large heterogeneity in the time since or end date of 
chemotherapy; therefore, these studies could not be properly compared to the results 
of the present study. Notably, the average VO2peak in patients post chemotherapy 
showed similar impairment in cardiac capacity as that observed among 1052 women 
with a myocardial infarction (15.4±4.0 ml/kg/min, measured about 14 weeks after the 
event) (Kavanagh et al., 2003). The study population of these cardiac patients was of 
comparable age (58.5±9.8 years) and BMI (26.7±5.1 kg/m2) and followed a similar 
testing protocol on a cycle ergometer as the present study. 
Interestingly, in contrast to the objective measures of cardiorespiratory 
function, our attending oncologists (without being aware of the CPET results) 
assessed the performance of the majority of patients as ECOG=0, i.e. as fully active, 
able to carry on all pre-disease activities of daily living without restrictions. These 
results emphasize that impaired cardiorespiratory fitness is prevalent among breast 
cancer patients, and should be monitored and counteracted to avoid further negative 
consequences. Low exercise levels after breast cancer treatment should be avoided, 
because lack of exercise is an established predictor of mortality in both breast cancer 
patients and healthy women (Blair et al., 1996; Peel et al., 2009). Furthermore, low 
cardiorespiratory fitness has been observed as significant determinant of 
dependence and functional limitations in daily living among older adults (Sweeney et 
al., 2006). 
Furthermore the impact of cancer treatment on the complex oxygen cascade, 
which involves several components of the respiratory and cardiovascular systems, is 
only marginally understood (Lakoski et al., 2012). The inclusion of three different 
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fitness parameters in our analysis provides further insight into the impact of 
chemotherapy on specific organs and functions within the cardiorespiratory system. 
VO2peak was chosen as a global parameter, which is influenced by oxygen uptake in 
the lung (ventilation and gas exchange), oxygen delivery (heart and blood), and 
peripheral oxygen extraction (metabolism on muscular level) (American Thoracic & 
American College of Chest, 2003). Because VO2peak depends on maximal effort and 
not all patients are willing or able to spend maximal effort, submaximal parameters, 
such as VT and HR50, are considered. VT provides insight into energy metabolism 
(aerobic vs. anaerobic) in the muscle and is defined as the point during graded 
exercise at which ventilation increases disproportionately to O2 uptake. Heart rate at 
50 Watts (HR50) or at a given submaximal work load provides information regarding 
the heart rate response, an important contributor to exercise intolerance. Our multiple 
regression analyses revealed that chemotherapy treatment has a significant impact 
on VO2peak, independent of other influencing factors such as age, BMI, or previous 
regular aerobic exercise. Effects of chemotherapeutic agents on different organ 
components of the oxygen system (e.g. the respiratory, cardiac, blood, vascular, or 
skeletal muscle functions) have been observed or hypothesized, potentially 
contributing to impaired cardiorespiratory fitness (Lakoski et al., 2012). Our adjusted 
regression analyses showed that HR50 was significantly affected by chemotherapy 
treatment. One can speculate that this observation is related to an impaired oxygen 
transportation of the blood which is compensated by a higher heart rate. VT was not 
significantly associated with chemotherapy, suggesting that there is no substantial 
impairment in skeletal muscle function as a result of chemotherapy treatment.  
However, the direct effects of cancer therapy are not easy to distinguish from 
indirect effects of therapy, such as detraining or changes in body weight and 
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composition as consequence of physical inactivity. Reduced physical activity may 
also be a potential consequence of poor cardiorespiratory fitness post cancer 
therapy. Cancer-related fatigue, which often persists during and after anti-cancer 
therapy and lack of knowledge of the benefits of effects of exercise, might increase 
sedentary behavior. Among breast cancer patients, a significant reduction in physical 
activity during cancer therapy has been observed, with a large proportion of women 
remaining inactive or demonstrating reductions in physical activity level post therapy 
compared to pre-diagnosis (Huy, Schmidt, Vrieling, Chang-Claude, & Steindorf, 
2012). 
To counteract this vicious cycle (i.e. low fitness leading to decreased activity 
leading to further decreased fitness), physicians and health professionals should 
encourage breast cancer patients to be physically active during therapy and to 
engage in exercise programs. There is strong evidence from randomized intervention 
studies that even strenuous exercise, including aerobic as well as resistance training, 
is feasible and can be safely performed in breast cancer patients during and after 
therapy (Cheema, Gaul, Lane, & Fiatarone Singh, 2008). A meta-analysis of 
endurance exercise interventions in breast cancer patients reported an average 
14.8% increase in VO2peak (Kim, Kang, & Park, 2009). A recent meta-analysis by 
Jones and colleagues reported similar cardiorespiratory fitness benefits among 
cancer patients participating in exercise programs (L. W. Jones et al., 2011). 
There are several limitations to this study. The investigated size of the 
treatment groups was unequal, because the studies (BEST and BEATE) were not 
primarily designed for these comparisons. Additionally, the cross-sectional design 
(i.e. using the baseline measurements only) limits causal inferences. Measurements 
of cardiorespiratory fitness are repeated at several time points in our intervention 
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trials, therefore longitudinal investigations are possible in the future. A methodological 
issue is that our exercise protocol started at a relatively high load level (50 watts). VT 
was reached at an average of 47 watts, which is within the first exercise stage. The 
VT would be more easily identifiable and determined better if at least one complete 
exercise stage was achieved below the anticipated VT or by using a ramp 
incremental test protocol. Therefore the VT results must be interpreted with caution. 
Given the problems with VT, future studies should elucidate to importance of 
measuring VT in cancer patients by evaluating the suitability of different testing 
protocols to detect VT more precisely. 
Strengths of our study include the use of the gold standard of cardiorespiratory 
fitness testing for the assessment of overall cardiorespiratory function. The additional 
investigation of submaximal measures, (i.e. VT and HR50) provides insight into the 
effects on muscular metabolic function and cardiocirculatory values. Submaximal 
parameters are independent of maximal effort. Because 46 of 222 participants could 
not reach the criteria for maximal effort, the submaximal data still provided relevant 
information on the patients’ cardiorespiratory fitness. In the absence of maximal 
exertion results, this data can be used to advise patients on endurance training 
prescriptions. Furthermore, the present study utilized information from a relatively 
large patient group and assessed many cofactors, which enabled adjusted 
regression modeling. Various breast cancer treatment characteristics were explored. 
These subgroups were recruited under comparable conditions from the same 
population source resulting in reliable findings. 
In conclusion, breast cancer patients had marked and significantly impaired 
cardiorespiratory function during and post chemotherapy. The impact on VO2peak 
appears to accumulate over the course of chemotherapy, while HR was already 
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impaired during the first chemotherapy cycles. However, there was no significant 
association between chemotherapy treatment and VT. Overall, our data suggest that 
chemotherapy may adversely affect cardiorespiratory fitness by negatively 
influencing the oxygen delivery system rather than impacting metabolic muscle 
function. 
These findings underline the need of systematic exercise training to counteract 
the loss of cardiorespiratory fitness during the anti-cancer treatment in breast cancer 
patients. In conjunction with the recommendations of other studies (S. B. Jones et al., 
2013; Strasser, Steindorf, Wiskemann, & Ulrich, 2013), exercise therapy should 
become a substantial and integrative part of supportive oncology therapy, with the 
ultimate goal to mitigate treatment-related side effects and improve quality of life and 
survival after breast cancer. 
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Abstract 
Aim 
Muscle strength has been associated with a decreased mortality risk and reduced 
side-effects in oncologic patients. However, little is known about how muscle strength 
is affected by cancer therapy. We investigated muscle strength in breast cancer 
patients during treatment and also compared it with healthy individuals. 
Methods 
Breast cancer patients (N=255), staged 0-III, aged 54.4±9.4 years, were categorized 
into four groups according to their treatment status. Their muscle function was 
assessed with gold standard method by maximal isokinetic peak torque (MIPT) 
(60°/s, 180°/s) and maximal voluntary isometric contraction (MVIC) tests in lower and 
upper extremity muscle groups. Additionally, muscular fatigue index (FI%) and 
shoulder flexibility was evaluated. Healthy women (N=26), aged 53.3±9.8 were tested 
using the same method. Analysis of covariance was used to estimate the impact of 
different cancer treatments on muscle function with adjustment for various clinical 
and socio-demographic factors. 
Results 
Consistently lower muscle strength and higher FI% was measured in knee strength in 
patients after chemotherapy. On average, patients had up to 25% lower strength in 
lower extremities and 12-16% in upper extremities in MVIC and MIPT during cancer 
treatment compared to healthy women. No substantial difference between patient 
groups in shoulder strength, but significantly lower shoulder flexibility in patients with 
radical mastectomy was measured. No serious adverse events were reported. 
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Conclusions 
Patients showed markedly impaired muscle strength after adjuvant therapy. The 
clinically relevant decrease underlines the need of exercise therapy as early as 
possible in order to prevent or counteract the loss of muscle function. 
Keywords 
isokinetic, isometric, multi-joint, muscle function, chemotherapy 
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Introduction 
Cancer-related muscle dysfunction is a broad clinical challenge, which is not 
restricted to palliative or advanced stage patients as it has also been observed in 
newly diagnosed patients with low tumor burden (Christensen et al., 2014; Villasenor 
et al., 2012). Many factors can affect skeletal muscle function including age, 
comorbidities, malnutrition, physical inactivity, tumor-derived factors, systemic and 
local cancer treatments, and supportive care medication (Lakoski, Eves, Douglas, & 
Jones, 2012). A prospective cohort study (HEAL) revealed a high prevalence of 
sarcopenia and its association with a higher all-cause mortality hazard ratio (HR) of 
2.86 in breast cancer (BC) survivors (Villasenor et al., 2012). Low muscle strength 
and physical inactivity can be a predictor for persistent fatigue in older, long-term BC 
survivors (Winters-Stone, Bennett, Nail, & Schwartz, 2008). BC patients undergoing 
adjuvant chemotherapy (CT) reduce their daily energy expenditure during therapy, 
which is associated with a loss of muscle mass (Demark-Wahnefried et al., 2001; 
Huy, Schmidt, Vrieling, Chang-Claude, & Steindorf, 2012). Furthermore, it was shown 
that skeletal muscle status is of clinical relevance since it is associated with treatment 
complications and time-to-tumor progression (Prado et al., 2009). With regard to 
healthy older individuals, muscle strength, but not mass, was identified as a strong 
independent predictor of all-cause mortality (Newman et al., 2006). 
Based on the current knowledge of treatment related side-effects, it can be 
assumed that muscle function is affected by different cancer treatments, but the role 
of muscle strength during cancer treatment has been insufficiently investigated 
(Strasser, Steindorf, Wiskemann, & Ulrich, 2013). Since we recently reported that 
cardiorespiratory performance varies between patient groups defined by cancer 
treatment (Klassen et al., 2014) we would like to provide an overall picture of the 
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performance status and the different impact of several types of cancer treatment 
among BC patients by analyzing various muscle strength parameters. 
 
Methods 
Population 
For this analysis, baseline data of two randomized controlled exercise trials 
(RCTs) in BC patients were used, i.e. the BEATE-Study and the BEST-Study 
(ClinicalTrials.gov NCT01106820 and NCT01468766, respectively) (Potthoff et al., 
2013; Schmidt et al., 2013; Steindorf et al., 2014). These two RCTs investigated the 
effects of 12-week progressive resistance training in comparison to relaxation training 
in BC patients undergoing adjuvant CT (BEATE-Study) or adjuvant radiotherapy 
(BEST-Study). Women with histologically confirmed stage 0-III primary BC after 
lumpectomy or mastectomy were eligible for the studies. Further inclusion and 
exclusion criteria and more details of the RCTs are presented elsewhere (Potthoff et 
al., 2013; Schmidt et al., 2013). In a parallel intervention study (INVEST-Study) with 
identical surveys, 26 healthy age-matched control women participated in the same 
12-week progressive resistance training protocol to obtain comparison data. 
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Figure. 1: Time point of the strength testing in clinically important treatment groups of BC patients and 
healthy women 
 
Both RCTs were conducted with parallel designs at the National Center for 
Tumor Diseases (NCT) in Heidelberg, Germany. Based on the different clinically 
important treatment histories and the healthy subjects, five subgroups were defined: 
No CT, Started (adjuvant) CT, Post neo-adj. CT, Post adj. CT, and healthy women. 
Patients recruited in the BEST-Study had the baseline strength testing within 14 days 
before starting radiotherapy. Of these participants, a majority had received surgery 
only (No CT, n=105), while some had received CT in the adjuvant (Post adj. CT, 
n=28) or neo-adjuvant (Post neo-adj. CT, n=31) CT setting. Patients enrolled in the 
BEATE-Study (Started CT, n=91) performed baseline strength testing at the end of 
the first or second CT cycle (see Figure 1). 
 
Assessment of muscle function 
Test system 
Isokinetic and isometric muscle strength were measured by using IsoMed 
2000-system B-series version (D&R Ferstl GmbH, Hemau, Germany). The use of 
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isokinetic dynamometer is valid and reliable (Dirnberger, Wiesinger, Kosters, & 
Muller, 2012) and considered a gold standard method to evaluate strength in cancer 
patients (Christensen et al., 2014), (Jones et al., 2010; Kilgour et al., 2010; Weber et 
al., 2009). 
 
Muscle function parameters 
Maximal isokinetic peak torque (MIPT) was tested for shoulder external and 
internal rotation, and for knee extensors and flexors at the angular velocities of 60°/s 
and 180°/s. The range of motion (ROM) for isokinetic knee measurement was limited 
between the angles from 10° to 90°. The position of dynamometer for shoulder 
rotation was tilted at 40° of abduction. The ROM for isokinetic testing was from 10° 
external rotation to 70° internal rotation. The MIPT for shoulder rotation was 
calculated for dominant side. 
With this device we also measured the maximal voluntary isometric contraction 
(MVIC) for shoulder internal rotator in the position of 43° and knee extensor muscles 
in the position of 35° (0° is straight leg), which sustainably were the strongest angle 
positions. For BC patients we calculated MVIC on the operated and non-operated 
side. For healthy women we calculated MVIC from the mean of left and right side. 
Muscular fatigue was determined by the calculation of the peak torque decline 
at 60°/s in knee extensors of the dominant leg. Therefore we used the muscular 
fatigue index: FI% = [(peak torque of initial three repetitions –peak torque of final 3 
repetitions) / peak torque of initial three repetitions] × 100, an adapted formula as 
described by Kannus (Kannus, 1994) to define the ability of an individual to maintain 
a level of performance. A high FI% indicates that muscles fatigue quickly. The peak 
torque of the first repetition overall was markedly lower than that of the second 
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repetition, and it was considered as a first “attempt” for the patient, it was omitted 
from the calculation of the initial peak torque values. 
Additionally, we measured the ROM in the arm elevation with a goniometer in 
a standardized supine lying position to elicit the flexibility limitations after surgery in 
both the operated and healthy sides. 
 
Testing protocol 
Participants were secured using thigh, pelvic and torso straps to minimize 
extraneous body movements. The subjects were permitted to use the handlebars on 
both sides of the IsoMed 2000 chair for additional stability during leg testing, but not 
for shoulder testing. For the MVIC testing, the participants were instructed to push as 
hard as possible against the fixed lever arm. Contraction time for MVIC was restricted 
to six seconds for each position. Each subject performed 10 maximal reciprocal 
contractions in both angular velocities for MIPT. During testing, both the subject and 
the instructor were able to see the strength curve on the monitor. Subjects were 
given verbal encouragement to generate the highest possible strength. Each torque 
artifact resulting from deceleration, which often exceeds the true peak torque, was 
removed by using a filter; only gravity corrected data was used for analysis. 
 
Data analysis 
Clinical and sociodemographic data were investigated by descriptive analyses 
for the entire study population. Between-group differences were assessed using χ2 
or Fisher’s exact test for categorical variables, and using one-way analysis of 
variance (ANOVA) for continuous variables. Analyses of covariance (ANCOVA) 
models were used to test whether the muscle function parameters differed between 
the four cancer treatment groups and in comparison with healthy individuals. We 
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calculated models adjusted for covariates that seemed biologically reasonable 
influencing factors. The included covariates are reported within the results section. 
Presented here are the parsimonious models including the significant covariates and 
those that changed the treatment estimate by >10%. Sensitivity analyses with 
different adjustment sets were performed to investigate the stability of the models. 
The ROM in the shoulder of the operated side was adjusted for the operation 
type (radical mastectomy and partial mastectomy). All statistics were performed using 
SAS 9.3 (SAS Institute Inc. NC, USA). The level of significance was set at p < 0.05. 
 
Results 
Participant characteristics 
Participant characteristics stratified by treatment groups are presented in 
Table 1. All patients underwent surgical resection with mean (±SD) time to strength 
assessment of 65.2 ± 49 days. According to the different treatment settings, there 
were significant group differences in the timeframe between patients’ surgery and the 
strength assessment (p <.001). The longest time period from surgery to muscle 
strength testing was 180.1 ± 50.5 days in the Post adj. CT group. The shortest period 
was 45.5 ± 12.7 days in the No CT group. Muscle strength testing was 76.4 ± 48.2 
days after CT in the Post neo-adj. CT group and 27.6 ± 15.4 days in the Post adj. CT 
group. The group with No CT was older (57.1 ± 8.7 years) than the group Post neo-
adj. CT (51.1 ± 9.3 years), Started CT group (52.6 ± 9.9 years) and Post adj. CT 
group (54.3 ± 7.9 years). Healthy controls had a mean age of 53.3 ± 9.8 years. There 
were no significant differences between the treatment groups in weight, height, body 
mass index (BMI) and in the Eastern Cooperative Oncology Group (ECOG) status 
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classified by the oncologists. Furthermore, no substantial differences in sport activity pre-diagnosis were observed between patient 
groups. The healthy controls had a higher level of moderate physical activity. 
Table 2: Characteristics of the population 
 
TOTAL 
Breast cancer treatment groups  
Healthy 
women 
 
 No CT Started CT 
Post neo-adj. 
CT Post adj. CT P* P** 
Number of women  281 105 91 31 28  26  
Age, mean (SD)  54.3 (9.4) 57.1 (8.7) 52.6 (9.9) 51.1 (9.3) 54.3 (7.8) 0.0011 53.3 (9.8) 0.0027 
Weight, mean (SD)  72.2 (13.9) 73.6 (13.6) 71.7 (14.0) 71.0 (11.3) 74.6 (18.4) 0.60 67.3 (11.4) 0.24 
Height, mean (SD)  165.9 (6.6) 164.9 (6.9) 166.3 (6.7) 166.1 (4.8) 167.3 (6.9) 0.26 166.9 (6.7) 0.33 
BMI, mean (SD)  26.3 (5.0) 27.1 (5.1) 25.9 (4.9) 25.8 (4.3) 26.5 (5.5) 0.33 24.2 (4.2) 0.077 
Menopausal status, n 
(%) 
pre 
67 26% 19 18% 37 41% 5 16% 6 21% 0.0035 n.a.  n.a. 
 peri 29 11% 10 9% 8 9% 7 23% 4 14%     
 post 147 58% 73 69% 39 42% 18 58% 17 61%     
 missing 12 5% 3 4% 7 8% 1 3% 1 4%     
Days since surgery, mean (SD) 65.2 (49.0) 45.5 (12.7) 56.8 (22.7) 55.9 (48.2) 180.1 (50.5) <.001 n.a.  n.a. 
Days since CT end, mean (SD) 55.1 (44.6) n.a.  n.a.  76.4 (48.2) 27.6 (15.4) <.001 n.a.  n.a. 
Mastectomy, n (%) yes 55 22% 4 4% 33 37% 11 36% 7 25% <.001 n.a.  n.a. 
Partial mastectomy, n 
(%) 
yes 
197 77% 101 96% 55 60% 20 64% 21 75%     
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TOTAL 
Breast cancer treatment groups  
Healthy 
women 
 
 No CT Started CT 
Post neo-adj. 
CT Post adj. CT P* P** 
 missing 3 1%   3 3%         
Lymph nodes 
dissected, n (%) 
none 11 4% 10 9.5% 1 1.1%     <.001 n.a.  n.a. 
sentinel 147 58% 76 72% 48 52% 14 45% 9 32%     
 axillary 94 37% 18 17% 40 44% 17 55% 19 68%     
 missing 3 1% 1 1% 2 2%         
Stage, n (%) 0 15 6% 13 12%   2 7%   <.001 n.a.  n.a. 
 1 118 46% 65 62% 36 40% 10 32% 7 25%     
 2 94 37% 26 25% 43 47% 15 48% 10 36%     
 3 27 11% 1 1% 11 12% 4 13% 11 39%     
 missing 1 <1%   1 1%         
Taxane, n (%) yes 90 35% n.a.  32 35% 31 100% 27 96% <.001 n.a.  n.a. 
 missing 1 <1%   1 1.%         
Anthracycline, n (%) yes 131 51% n.a.  77 85% 29 96% 25 89% 0.23 n.a.  n.a. 
 missing 3 1%   1 1% 1 3% 1 4%     
Herceptine treatment, n 
(%) 
yes 16 6% 0 0% 4 4% 6 19% 6 21% <.001 n.a.  n.a. 
missing 1 <1%   1 1%         
Hormone therapy, n 
(%) 
yes 
79 31% 55 52% 0 0% 13 42% 11 39% <.001 n.a.  n.a. 
ECOG, n (%) 0 222 87% 93 89% 79 87% 27 87% 23 82% 0.49 n.a.  n.a. 
 1 25 10% 10 9% 6 6% 4 13% 5 18%     
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TOTAL 
Breast cancer treatment groups  
Healthy 
women 
 
 No CT Started CT 
Post neo-adj. 
CT Post adj. CT P* P** 
 2 1 <1% 1 1%           
 missing 7 3% 1 1% 6 6%         
FAQ physical fatigue, mean (SD)  39.4 (27.1) 35.0 (26.9) 44.0 (25.5) 45.0 (25.5) 56.7 (24.5) <.001 16.4 (18.3) <.001 
Depression (ADS), mean (SD) 25.1 (16.7) 26.6 (17.1) 25.6 (16.2) 28.9 (18.5) 26.0 (14.7) 0.83 11.8 (11.4) <.001 
Sports before diagnosis1, n (%)         
none 
98 35% 46 44% 21 23% 14 45% 9 32% 0.14 8 31% 0.0045 
>0-9 MET·h/wk 77 27% 25 23% 24 26% 7 23% 7 25%  14 54%  
>9-21 MET·h/wk 55 20% 19 18% 24 26% 6 19% 4 14%  2 8%  
>21 MET·h/wk 46 16% 14 13% 21 23% 4 13% 7 25%     
missing 5 2% 1 1% 1 1%   1 4%  2 8%  
Cyclinga, n (%) none 98 35% 38 36% 28 31% 14 45% 10 36% 0.87 8 31% 0.26 
 >0-1 h/wk 85 30% 32 31% 31 34% 9 29% 11 39%  2 8%  
 >1-3 h/wk 60 21% 22 21% 20 22% 6 19% 3 11%  9 34%  
 >3 h/wk 31 11% 10 9% 12 13% 2 7% 2 7%  5 19%  
 missing 7 3% 3 3%     2 7%  2 8%  
BMI body mass index, CT chemotherapy, ECOG Eastern Cooperative Oncology Group, MET metabolic equivalent, SD standard deviation, FAQ Fatigue 
Assessment Questionnaire with items for physical fatigue, ADS German depression scale based on Center for Epidemiological Studies Depression Scale (CES-
D), 
a Exercise behavior in the year before breast cancer diagnosis with self-developed surveys abstracted from the International Physical Activity Questionnaire 
(IPAQ) 
* P-value for one-way ANOVA for continuous variables, Chi2 or Fisher’s exact test for categorical variables only for breast cancer patient groups 
** P-value for one-way ANOVA for continuous variables, Chi2 or Fisher’s exact test for categorical variables for all groups 
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Maximal voluntary isometric contraction (MVIC) 
The adjusted means and 95% confidence intervals (CI) for knee extensors and internal rotators in the operated and non-
operated shoulder for MVIC are presented in Table 2. 
Table 3: Maximal voluntary isometric contraction (MVIC) in N·m in different treatment groups and healthy subjects 
 
Data presented as adjusted mean with 95% confidence intervals (CI) 
a Model for knee extension is adjusted for age, BMI (17-<25, 25-30, >30 kg/m2), weight, drugs which influence the muscle tonus, antidepressants, regular cycling 
and previous experience in resistance training 
b Model for shoulder rotation is adjusted for age, BMI (17-<25, 25-30, ≥30 kg/m2) and previous experience in resistance training 
c In healthy women: mean of left and right arm 
MVIC maximal voluntary isometric contraction, N·m Newton meter, op operated side 
Concerning MVIC of knee extensors, the BC treatment groups had impairments of 9-14% in strength in comparison to healthy women, 
but these differences did not reach statistical significance. There were also no statistically significant differences between the BC 
patients groups in shoulder MVIC, neither for the operated nor for the non-operated side. However, healthy women had 12-16% higher 
MVIC in shoulder internal rotators which is significantly different in comparison to the BC patient groups. 
 Breast cancer treatment groups  
Measure/Treatme
nt 
No CT 
(n = 105) 
A 
Started CT 
(n = 91) 
B 
Post neo-adj. CT 
(n = 31) 
C 
Post adj. CT 
(n = 28) 
D 
Significant 
differences 
between 
patient 
groups 
Healthy women 
(n = 26) 
E 
Significant 
differences 
to healthy 
women 
Knee Extensiona 
126.8 (120.2, 
133.5) 
125.4 (118.1, 
132.7) 
119.0 (108.1, 
129.9) 
122.8 (111.5, 
134.1) 
n.s. 
138.5 (127.4, 
149.5) 
n.s. 
Shoulder internal 
rotation (op)b 
28.5 (27.3, 29.7) 29.7 (28.3, 31.0) 28.3 (26.0, 30.6) 29.4 (27.0, 31.7) n.s. 33.8 (31.4, 36.2)1 
A/E, B/E, 
C/E 
Shoulder internal 
rotation (non-op) b 
30.1 (28.8, 31.3) 30.9 (29.5, 32.3) 28.8 (26.4, 31.1) 29.1 (26.5, 31.6) n.s. 33.8 (31.4, 36.2)c 
A/E, B/E, 
C/E, D/E 
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Maximal isokinetic peak torque (MIPT) 
Adjusted means and 95% CI of MIPT in knee and shoulder muscles in two speeds for the treatment groups and healthy women 
are reported in Table 3. BC patient groups had, on average, 5-20% decreased MIPT in knee extensors and a 7-25% decrease in knee 
flexors compared to healthy women measured with 60°/s (see Figure 2). The most impaired groups were those with completed 
chemotherapies. Isokinetic shoulder internal rotator strength was significantly impaired in all cancer treatment groups when compared 
to healthy controls. 
Table 3: Maximal isokinetic peak torque (MIPT) in N·m in different treatment groups and healthy subjects 
 Breast cancer treatment groups  
Measure/Treatment No CT 
(n = 105) 
A 
Started CT 
(n = 91) 
B 
Post neo-adj. 
CT 
(n = 31) 
C 
Post adj. CT  
(n = 28) 
D 
Significant 
differences 
between patient 
groups 
Healthy 
women 
(n = 26) 
E 
Significant 
differences to 
healthy women 
Knee Extensiona in 60°/s 
88.6 (83.2, 
94.1) 
92.6 (86.5, 
98.7) 
84.0 (76.1, 91.9) 
77.7 (69.9, 
85.5) 
A/D, B/D 
97.5 (89.5, 
105.6) 
A/E, C/E, D/E 
Knee Flexiona in 60°/s 
57.2 (53.7, 
60.8) 
64.5 (60.6, 
68.4) 
53.1 (47.3, 58.9) 
51.9 (45.9, 
57.9) 
A/B, A/C, B/C, 
B/D 
69.2 (63.3, 75.1) A/E, C/E, D/E 
Knee Extensiona in 180°/s 
56.6 (53.3, 
59.9) 
58.4 (54.7, 
62.1) 
51.5 (46.7, 56.3) 
47.2 (42.5, 
51.9) 
A/D, B/C, B/D 63.5 (58.6, 68.3) C/E, D/E 
Knee Flexiona in 180°/s 
48.9 (46.2, 
51.7) 
53.5 (50.5, 
56.5) 
43.2 (38.7, 47.7) 
43.4 (38.8, 
48.1) 
A/B, B/C, B/D, 59.6 (55.0, 64.1) A/E, B/E, C/E, D/E 
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Shoulder internal rotationb 
in 60°/s 
25.6 (24.6, 
26.6) 
26.9 (25.8, 
28.0) 
26.0 (24.1, 27.9) 
25.6 (23.7, 
27.5) 
n.s. 30.4 (28.4, 32.3) A/E, B/E, C/E, D/E 
Shoulder external rotation 
b in 60°/s 
8.7 (8.0, 9.4) 8.8 (8.0, 9.5) 9.2 (7.9, 10.5) 8.3 (7.0, 9.6) n.s. 10.8 (9.4, 12.2) n.s. 
Shoulder internal rotation b 
in 180°/s 
23.7 (22.6, 
24.7) 
22.4 (21.4, 
23.4) 
22.8 (21.0, 24.6) 
21.7 (19.9, 
23.6) 
n.s. 26.3 (24.3, 28.2) n.s. 
Shoulder external rotation 
b in 180°/s 
6.0 (5.4, 6.7) 5.6 (5.0, 6.2) 5.7 (4.7, 6.8) 5.5 (4.4, 6.6) n.s. 7.4 (6.3, 8.6) n.s. 
Data presented as adjusted mean with 95% confidence intervals (CI) 
a Model for knee extension and flexion is adjusted for age, BMI (17-<25, 25-30, ≥30 kg/m2), weight, drugs which influence the muscle tonus, antidepressants, 
regular cycling and previous experience in resistance training 
b Model for shoulder rotation is adjusted for age, BMI (17-<25, 25-30, ≥30 kg/m2) and previous experience in resistance training 
MIPT maximal isokinetic peak torque, N·m Newton meter 
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Shoulder internal rotators of the dominant side were 12-16% weaker among 
the treatment groups in comparison to healthy controls, but within cancer patients, no 
between-group differences were found. There were no significant differences in 
shoulder MIPT between BC patients with regard to the operated side (data not 
shown). 
 
Figure 2: Adjusted means of maximal isokinetic peak torque (MIPT) at 60°/s of extension/flexion knee 
with 95% confidence intervals (CI), 
* Significant differences to Post neo-adj. CT (p=0.037) and Post adj. CT (p<0.001), 
** Significant differences to No CT (p=0.0023), Post neo-adj. CT (p<0.001) and Post adj. CT (p<0.001) 
Models adjusted for age, BMI (17-<25, 25-30, >30 kg/m2), weight, drugs which influence the muscle 
tonus, antidepressants, regular cycling and previous experience in resistance training 
 
In the ANCOVA model, the covariates which had a significant impact on the 
strength of lower extremities were cancer treatment, age, BMI, weight, drugs which 
influence muscle tonus and mood (antidepressants), previous experience in 
resistance training and regular cycling (Table 2, 3). Other potential confounding 
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factors like orthopedic dysfunctions, cardiovascular restrictions, cancer-related 
physical fatigue (assessed by the Fatigue Assessment Questionnaire), ECOG and 
tumor stage showed no significant impact on muscle strength and no confounding on 
the group effect. 
Significant covariates in the model for strength of the operated shoulder were 
cancer treatment, age, weight and previous experience in resistance training (Table 
2, 3). Operation type, number of dissected lymph nodes, preexisting injuries in 
shoulder/arm and time since BC surgery had no significant impact. 
 
Muscular fatigue (FI %) 
The greatest fatigue in muscular performance within 10 repetitions could be 
shown in the Post adj. CT group, followed by the groups Post neo-adj. CT and No 
CT. All patient groups fatigued faster compared to the healthy individuals, except 
those patients in the Started CT group (Figure 3). 
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Figure 3: Muscular fatigue over a set and muscular fatigue index (FI % = [(peak torque of initial 3 
repetitions –peak torque of final 3 repetitions) / peak torque of initial 3 repetitions] × 100) in different 
treatment groups in knee extensors of the dominant leg. Presented are the unadjusted group means. 
First repetition omitted from analysis of FI% 
 
Shoulder flexibility 
The ANCOVA model showed no significant association with the treatment 
groups. However, they indicated that the type of surgery and the length of time 
elapsed since BC surgery was independently influencing factors for shoulder 
flexibility. The operated side was, on average, 12% less flexible in patients with 
radical mastectomy compared to partial mastectomy. Furthermore, there was a 
significant difference in flexibility of the arm elevators in patients <6 weeks post-
surgery (mean of 83°) and those who were tested 6-12 weeks post-surgery (mean of 
90°). No significant differences were identified in patients who were tested >12 weeks 
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post-surgery (mean of 95°) in comparison to those tested between 6-12 weeks post-
surgery. 
 
Discussion 
The performed isokinetic and isometric tests were safe and feasible. No 
adverse events were observed; only sporadic muscle soreness was reported by a 
few patients. Overall, we observed that BC patients undergoing acute cancer 
treatment had remarkably impaired strength capacity in both isokinetic and isometric 
values as well as in muscular fatigue compared to healthy individuals. Specifically, 
patients who had received chemotherapy in their treatment history were the most 
affected. 
To our knowledge, this is the first study investigating isometric and isokinetic 
strength performance in different clinically important BC patient groups. Therefore, 
our results provide new insights into muscle strength performance of BC patients 
from several perspectives. 
Our findings are in line with other studies showing an impaired muscle status 
in cancer patients. Most published studies in the field assessed strength performance 
via hand-grip (Kilgour et al., 2013; Platt, Gross, & Davis, 2014; Schneider, Hsieh, 
Sprod, Carter, & Hayward, 2007) or hand-held dynamometry (Harrington et al., 2011; 
Hummler et al., 2014), with functional tests (Schneider et al., 2007; Winters-Stone et 
al., 2008) or by using the one repetition maximum method (Courneya et al., 2007; 
Galvao et al., 2009; Ruiz et al., 2009). There are also studies using isokinetic testing 
procedures, but these studies had low sample sizes, and focused on other research 
questions (Fong et al., 2013; Kilgour et al., 2010; Wilcock et al., 2008). 
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Regarding the reported performance differences between cancer patients and 
matched healthy controls, the studies mentioned above reported larger differences in 
strength performance than we observed in our studies. For example, we detected 
mean differences between 12-16% in MVIC for the internal shoulder rotators, 
whereas a study published by Harrington et al. (Harrington et al., 2011) reported a 
26% reduction in a comparable patient group. Lastly, differences with regard to 
strength testing procedures might be of importance. Hand-held dynamometry is 
known to be a valid and reliable testing procedure, but relatively large measurement 
errors can occur based on an insufficient standardization of the testing position 
(Knols, Stappaerts, Fransen, Uebelhart, & Aufdemkampe, 2002). Computer-based 
stationary dynamometry with fixed and therefore highly standardized testing positions 
will therefore provide more accurate testing values (Kannus, 1994). 
One of the new insights of this study comes along with the isokinetic testing 
protocol. Since we included two different testing speeds in the protocol, we were able 
to draw conclusions in relation to muscle fiber activation. Research has shown that at 
lower angular velocities, muscle fibers I and II can be maximally activated, whereas 
with increasing speed, less slow twitch fiber (type I) will be recruited (Kannus, 1994). 
With regard to our findings, our results suggest that chemotherapy treatment does 
not have an impact on fiber activation since the isokinetic strength differences 
between the chemotherapy groups and the non-CT/started CT groups as well as the 
control group are comparable in both angular velocities. 
New insights could be also reported with regard to the interaction of CT and 
fatigue resistance of skeletal muscles. We observed that patients having received 
chemotherapy (nearly all treated with anthracycline) had less strength and greater 
muscular fatigue compared to BC patients without CT or just at the beginning of CT. 
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An explanation for these findings could be an inactivity-related shift of muscle fibers 
and a CT-induced change in mitochondrial capacity of muscle cells (Bonifati et al., 
2000). This is supported by the observation that CT caused severe reductions in 
myofiber size, neurogenic alterations and mitochondria-related damages in mice as 
well as in humans (Christensen et al., 2014; Scott et al., 2011). Furthermore, it is well 
known that BC patients reduce their physical activity level during the period of cancer 
treatment (Huy et al., 2012). Moreover, our patients reported less activity in the year 
before. These circumstances potentially lead to a loss of muscle strength, which can 
be supported by our objective data. In general, individual strength performance in 
cancer patients may be influenced by various contextual factors. Some of those 
factors are independent from the cancer setting (e.g. age or motivation of the patient) 
and some not (e.g. locoregional and systemic therapies, cancer related fatigue) 
(Knols et al., 2002). Receiving chemotherapy might be one of the most important 
factors as we already reported for cardiorespiratory fitness (Klassen et al., 2014), but 
the mechanisms (Bonifati et al., 2000; Gilliam & St Clair, 2011; Scott et al., 2011) and 
pathways (Egerman & Glass, 2014) of cancer treatment influences on muscle 
structure and function are not completely understood. 
Aside from reduced strength capacity, upper-body mobility restrictions 
represent a stressful physical limitation in patients undergoing BC surgery (Hayes et 
al., 2012). We measured a loss of shoulder mobility and decreased shoulder internal 
rotator strength, resulting in an impaired shoulder function, which was a result of 
mastectomy. Impaired shoulder function has been reported in many BC survivors 
even several years after surgery (Kootstra et al., 2013). Interestingly, the time 
difference between surgery and testing, type of surgery and pain are considered to 
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have no impact on shoulder strength; only flexibility, which was dependent on the 
type and time since surgery, was impaired. 
 
Strengths and limitations 
Our study has several strengths. We performed stationary isokinetic strength 
testing, which is the gold standard procedure for functional skeletal muscle 
assessment. Furthermore, we report data on a very large sample size (n=255) of 
early stage BC patients in a well-defined and clinically relevant time frame. Moreover, 
we were able to assess many relevant cofactors and include them in adjusted 
regression models on strength performance in clinically relevant subgroups. Lastly, 
the current study is the first which reports information about muscular fatigue in 
relation to different treatment settings and all patient data could be compared with an 
age matched healthy control group. 
This study did include some limitations. The sizes of the groups were unequal 
because the studies (BEST, BEATE and INVEST) were not primarily designed for 
these comparisons. Additionally, the cross-sectional design limits causal inferences. 
Furthermore, the healthy women were a convenience sample and despite matching 
by age-groups, differences need to be interpreted with caution. Nevertheless, the 
strength performance of our healthy participants was in line with comparably aged 
healthy women (Frontera, Hughes, Lutz, & Evans, 1991). 
 
Conclusions 
Our study showed that isometric and isokinetic strength testing appears to be 
safe in a large cohort of BC patients. We reported about significantly impaired 
isometric and isokinetic strength capacity with higher muscular fatigue in low 
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extremities and dysfunctions in shoulder mobility in our patients. Overall, receiving 
chemotherapy treatment seems to have the greatest impact on muscular strength. 
Based on these findings, the prevention of muscle dysfunction should be an 
important goal during cancer treatment and underlines the importance for the 
implementation of resistance training regimens during cancer treatment to mitigate or 
reverse muscle dysfunction. To further understand the mechanisms of muscular 
dysfunction in cancer patients, there is a need for the assessment of cellular muscle 
structure and biomarkers combined with accurate (gold standard) strength testing 
procedures. 
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Abstract 
Purpose 
Cancer survivors are recommended to perform 150 min/week of moderate or 
75 min/week of vigorous aerobic exercise, but it remains unclear how moderate and 
vigorous intensities can be prescribed. Therefore, it was investigated whether and 
how intensity prescriptions for healthy adults by the American College of Sports 
Medicine (ACSM) need to be adapted for breast cancer survivors.  
Methods 
52 breast cancer survivors (stage 0-III, age 52±9 years, BMI 25.4±3.5 kg/m2) 
performed cardiopulmonary exercise tests at the end of primary-therapy. Intensity 
classes defined as percentages of maximal heart rate (HRmax), heart rate reserve 
(HRR), and maximal oxygen uptake (VO2max) were compared to the ACSM’s intensity 
classes using oxygen uptake reserve as reference.  
Results 
The prescriptions for moderate and vigorous exercise intensities were significantly 
different between breast cancer survivors and healthy adults when using VO2max 
(moderate 50–66 vs. 46–63 and vigorous 67–91 vs. 64–90 %VO2max) or HRR 
(moderate 26–50 vs. 40–59 and vigorous 51–88 vs. 60–89 %HRR), but not when 
using HRmax (moderate 65–76 vs. 64–76 and vigorous 77–94 vs. 77–95 %HRmax).  
Conclusions 
In breast cancer survivors, intensity prescriptions for healthy adults result in 
considerably too intense training if HRR is used as guiding factor. Prescriptions using 
VO2max result in a slightly too low exercise intensity, whereas recommendations in 
percentages of HRmax appear valid.  
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Implications for Cancer Survivors 
Cancer survivors should not uncritically adopt exercise intensity prescriptions for 
healthy adults. Specific prescriptions for the studied population are provided. 
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Introduction  
Exercise training in breast cancer survivors has been demonstrated to be safe 
and to elicit numerous beneficial effects on the physiological and psychological level 
(Schmitz et al., 2010). These include improvements in aerobic fitness and muscular 
strength (evidence category A), quality of life, fatigue, anxiety, body composition, and 
body size (evidence category B) (Schmitz et al., 2010). Furthermore, increasing 
evidence from observational studies suggests that regular physical activity may 
extend survival (Holmes, Chen, Feskanich, Kroenke, & Colditz, 2005; Irwin & Mayne, 
2008). Therefore, exercise training is recommended by expert panels worldwide 
(Hayes, Spence, Galvao, & Newton, 2009; Rock et al., 2012; Schmitz et al., 2010) 
and has become a recognized part of supportive therapy. However, knowledge is still 
scarce about how to prescribe exercise training for cancer survivors. Especially the 
definition of adequate training intensities remains unclear (Jones, 2011). 
The American College of Sports Medicine’s (ACSM’s) exercise guidelines for 
cancer survivors  recommend to follow the exercise prescriptions for healthy adults, 
with specific adaptations based on the disease and treatment-related adverse effects 
(Schmitz et al., 2010). These prescriptions include 150 min/week of moderate-
intensity or 75 min/week of vigorous-intensity endurance exercise, adapted based on 
the abilities of cancer survivors (Physical Activities Guidelines Advisory Committee, 
2008; Schmitz et al., 2010). However, this adaptation is not specified and it remains 
unclear how moderate and vigorous exercise intensities can be defined in cancer 
survivors. Brisk walking might be moderate for one but near-maximal for another 
individual and, therefore, relative intensity prescriptions by means of heart rates, 
walking velocities or work rates on the cycle ergometer are needed. The ACSM 
provides such exercise intensity prescriptions for apparently healthy adults (Garber et 
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al., 2011) and in the absence of cancer-specific data this is also widely used for 
breast cancer survivors. Physicians and coaches can use various data of 
cardiopulmonary exercise tests (CPET) to look up prescriptions for different intensity 
classes in this table. For example, moderate intensity is classified as 64–76 % of 
maximal heart rate (HRmax) (Schmitz et al., 2010). If no measured HRmax is available, 
age-predicted maximum heart rate (APHRmax, 220 minus age) is often applied 
(Dimeo, Fetscher, Lange, Mertelsmann, & Keul, 1997; Musanti, 2012). Further 
options are to use percentages of maximal oxygen uptake (VO2max) or heart rate 
reserve (HRR, difference between resting heart rate and HRmax) (Garber et al., 2011). 
Some authors also prefer to derive exercise intensities from peak power output 
(PPO) which is not part of the ACSM’s intensity classification (Courneya et al., 2012).  
However, these intensity prescriptions for healthy individuals might not be 
valid for breast cancer survivors. Chemotherapy and thoracic radiation may impact 
the cardiac, pulmonary and vascular system, hemoglobin concentration, and skeletal 
muscle oxidative capacity (Lakoski, Eves, Douglas, & Jones, 2012). As a result, for 
example, 50 % of breast cancer survivors were observed to present with resting 
sinus tachycardia 20 months after anthracycline-taxane containing chemotherapy 
and/or therapy with the monoclonal antibody trastuzumab (Jones et al., 2006). An 
elevated resting heart rate reduces HRR and, therefore, intensity prescription in 
percentages of HRR might need to be adjusted. Similarly, VO2max is markedly 
reduced in breast cancer survivors compared to healthy individuals (Jones et al., 
2012; Klassen et al., 2014; Schneider et al., 2014), which might affect intensity 
prescription in percentages of VO2max. For training prescription, the interpretation of 
previous exercise intervention studies, and the design of future studies it is essential 
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to know whether and how intensity classification for healthy adults (Garber et al., 
2011) needs to be adapted for breast cancer survivors. 
Therefore, CPETs in breast cancer survivors were analyzed in the present 
study to (i) evaluate whether the exercise intensity classification for apparently 
healthy adults by the ACSM (Garber et al., 2011) is valid in breast cancer survivors 
and (ii) provide an adapted exercise intensity prescription table for breast cancer 
survivors to facilitate training recommendations and comparisons of previous training 
intervention studies that used different parameters for exercise prescription. Breast 
cancer survivors were investigated at the end of primary therapy to represent a point 
in time typical for the beginning of endurance training. 
 
Materials and Methods 
General design 
For the present analysis, data from two randomized controlled clinical exercise 
intervention trials were used: the BEST and BEATE study (ClinicalTrials.gov ID 
NCT01468766 and NCT01106820). In these studies, the effects of relaxation training 
(non-exercising social attention control group) vs. exercise training were investigated 
in breast cancer patients undergoing radiation and chemotherapy, respectively (for 
study design see (Potthoff et al., 2013) and (Schmidt et al., 2013)). Both studies were 
approved by the Ethics Committee of the Medical Faculty Heidelberg and respected 
human rights according to the Declaration of Helsinki. Written informed consent was 
obtained from all patients before enrolment. CPETs of the relaxation control group 
participants at the end of primary therapy were analyzed. Oxygen uptake reserve 
(VO2R, difference between resting and maximal oxygen uptake representing the 
individual range of exercise capacity) served as the reference to define intensity 
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classes (Garber et al., 2011). Individual linear regression equations were calculated 
from the CPET data with percentages of VO2R as the independent variable and 
percentages of HRR, HRmax, APHRmax, VO2max, and PPO as dependent variables to 
derive the intensity classes for the other parameters. The results were compared to 
the exercise intensity classification for apparently healthy adults by the ACSM 
(Garber et al., 2011). 
 
Participants 
Female patients with histologically confirmed primary breast cancer, stage 0 to 
III, age ≥18 years, and BMI ≥18 kg∙m-2 were included. Participants belonged to the 
non-exercising relaxation control group and were tested once 2 weeks before to 12 
weeks after the end of the primary therapy, i.e. surgery plus chemotherapy and/or 
radiation. Exclusion criteria were (i) acute infectious diseases, severe neurological, 
cardiovascular, respiratory or renal diseases, or other concurrent malignant diseases, 
(ii) intake of beta blockers or calcium channel blockers, (iii) premature cessation of 
the CPET due to medical reasons (e.g. ECG abnormalities or high blood pressure) or 
lack of spending maximal effort (respiratory exchange ratio (RER) <1.10 or HRmax 
<200 minus age (Midgley, McNaughton, Polman, & Marchant, 2007)), and (iv) 
completion of <2 exercise stages in the CPET to enable calculation of a regression 
equation. Eligibility for maximal exercise testing was approved by a study physician. 
Of 89 eligible patients, a total of 37 patients had to be excluded (beta or calcium 
channel blockade: n = 18, <2 exercise stages in the CPET: n = 5, premature 
cessation of the CPET due to medical reasons: n = 2, and lack of spending maximal 
effort: n = 12), resulting in a study population of n = 52. Patients’ characteristics are 
given in Table 1. 
Exercise training intensity prescription in breast cancer survivors
 
III. Publication  95 
Table 1: Patients’ characteristics (primary therapy included surgery plus chemotherapy and/or 
radiation; n = 52).  
Anthropometric data  
Age [years], mean ± SD 52 ± 9 
Height [cm], mean ± SD 168 ± 7 
Weight [kg], mean ± SD 71 ± 11 
BMI [kg∙m-2], mean ± SD 25.4 ± 3.5 
Breast cancer stage  
      0, n (%) 2 (4%) 
      I, n (%) 27 (52%) 
      II, n (%) 15 (29%) 
      III, n (%) 8 (15%) 
ECOG  
      0, n (%) 49 (94%) 
      1, n (%) 3 (6%) 
Therapy   
Surgery, n (%) 52 (100%) 
Chemotherapy, n (%) 32 (62%) 
Anthracyclines, n (%) 31 (60%) 
Taxanes, n (%) 31 (60%) 
Radiotherapy, n (%) 51 (98%) 
Targeted therapy, n (%) 8 (15%) 
Trastuzumab, n (%) 8 (15%) 
Hormone therapy, n (%) 31 (60%) 
Time since end of primary therapy [wk], mean ± SD 5 ± 3 
 
Determination of patients’ characteristics 
Height and body weight were measured in sportswear without shoes using a 
calibrated scale and a yardstick. Breast cancer stage, performance score (ECOG), 
and medication were derived from the patient’s medical records. Present medication 
was additionally asked prior to CPET. 
 
Cardiopulmonary exercise tests 
The CPETs were performed on an electronically braked cycle ergometer 
(Ergoselect 100, Ergoline, Bitz, Germany). All participants were familiar with the 
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CPET procedure from previous testing. The tests were preceded by a resting period 
of >3 min in a sitting position on the cycle ergometer to obtain resting values. The 
stepwise incremental exercise protocol started at 50 W and work rate was increased 
every 2 min by 25 W until voluntary exhaustion or occurrence of medical reasons for 
premature exercise cessation. Cadence was kept constant around 60 or 
65 revolutions per minute and participants were encouraged to spend maximal effort. 
A 12-lead ECG was recorded continuously and blood pressure was measured every 
2 min. Gas exchange measurements were performed continuously using a breath-by-
breath system (Ergostik, Geratherm Respiratory, Bad Kissingen, Germany). The 
metabolic device was calibrated before each test according to the instructions of the 
manufacturer using a 3 l syringe and gas of known concentration.  
 
Derived variables 
Gas exchange data and heart rate (HR) were time averaged over 30 s. 
Resting oxygen uptake (VO2) and HR were considered the last 30 s average value of 
the resting period. It was previously demonstrated that resting VO2 assessment in a 
sitting compared to a supine position does not affect the intercept and slope of 
%HRR-%VO2R relationship (Cunha, Midgley, Monteiro, & Farinatti, 2010). PPO was 
linearly interpolated if the last stage of the stepwise incremental protocol was not 
completed. VO2max and HRmax were determined as the highest 30 s average values 
during or immediately post exercise, respectively. RERmax was considered the 
highest 30 s average value during exercise. APHRmax was calculated using the 
formula 220 minus age (Dimeo, Fetscher, et al., 1997). VO2R was calculated as 
difference between VO2max and resting VO2. HRR was calculated as difference 
between HRmax and resting HR. Over the course of the exercise test, VO2 and HR 
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were averaged over the last 30 s of each exercise stage and the last 30 s of the test 
and were expressed in %VO2R, %VO2max, %HRR, %HRmax, and %APHRmax. 
 
Statistical analysis 
For each participant, individual linear regression equations were calculated 
using percentages of VO2R as independent variable and percentages of HRR, 
VO2max, HRmax, APHRmax, and PPO as dependent variables. From these individual 
equations, intensity classes according to the intensity classification for apparently 
healthy adults by the ACSM (Garber et al., 2011) were calculated for breast cancer 
survivors using percentages of VO2R as reference. Obtained values were compared 
with the ACSM’s values for 30, 40, 60, and 90 % VO2R by means of one-sample t-
tests. To control for the familywise error, a sequential Bonferroni correction was 
applied and p < 0.017 was considered significant for this analysis. Slopes and 
intercepts of the individual linear regression equations were averaged across 
participants to receive mean regression equations. In addition to the data of the 
whole group, subgroup data for participants with and without chemotherapy were 
analyzed. Slopes and intercepts of the regression equations as well as values for 30, 
40, 60, and 90 % VO2R were compared between subgroups using unpaired 
Student’s t-tests. Data are presented as means ± standard deviations (SD) and 95 % 
confidence intervals (95% CI). 
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Results 
CPET outcomes 
Resting and maximal CPET data are given in Table 2. The relationships 
between different CPET variables observed in breast cancer survivors compared to 
those in healthy adults given by the ACSM data are displayed in Figure 1. The 
regression between percentages of PPO and VO2R (not part of the ACSM’s intensity 
classification) averaged % PPO = 1.08 ± 0.26 %VO2R - 7.45 ± 25.03 (n = 52). Slopes 
and intercepts of the regressions were not significantly different between breast 
cancer survivors with and without chemotherapy (all p ≥ 0.18, HR: n = 31 with 
chemotherapy vs. n = 20 without chemotherapy; VO2: n = 32 with chemotherapy vs. 
n = 20 without chemotherapy). 
Table 2: Resting and maximal data of the cardiopulmonary exercise test (n = 52, VO2: oxygen uptake, 
HR: heart rate, PPO: peak power output, VO2max: maximal oxygen uptake, RERmax: maximal 
respiratory exchange ratio, HRmax: maximal heart rate, APHRmax: age-predicted maximal heart rate). 
 Parameter Mean ± SD 
Resting VO2 [ml∙min-1] 247 ± 60 
Resting VO2 [ml∙min∙kg-1] 3.5 ± 0.7 
Resting HR [min-1] 83 ± 12  
Resting sinus tachycardia [n (%)] 4 (8%) 
PPO [W] 123 ± 26 
PPO [W∙kg-1] 1.7 ± 0.4 
VO2max [ml∙min-1] 1580 ± 390 
VO2max [ml∙min∙kg-1] 22.6 ± 6.3 
RERmax [ ] 1.18 ± 0.09 
HRmax [min
-1] 158 ± 14 
APHRmax [min
-1] 168 ± 9 
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Figure 1: Linear regressions between percentages of VO2R and percentages of (A) HRR, (B) HRmax, 
(C) APHRmax, and (D) VO2max in breast cancer survivors at the end of primary therapy (observed 
data, means and 95% confidence bands) and healthy individuals (data provided by the ACSM, mean 
regression lines,  n = 51 for HR, n = 52 VO2). 
 
Exercise intensity classification 
Intensity classes observed in breast cancer survivors compared to the data of 
healthy adults provided by the ACSM (Garber et al., 2011) are given in Table 3. 
Percentages of HRR were significantly lower in breast cancer survivors than in 
healthy adults within the range of intensities relevant for training prescription of 30, 
40, and 60 % VO2R (all p < 0.001, n = 51). Percentages of HRmax corresponding to 
30, 40, and 60 % VO2R were not significantly different between breast cancer 
survivors and healthy adults (all p ≥ 0.29, n = 51). Percentages of APHRmax in breast 
cancer survivors corresponding to 30 and 40 % VO2R were also not significantly 
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different from HRmax in healthy adults (all p ≥ 0.07), but percentages of APHRmax 
corresponding to 60 % VO2R were significantly lower (all p < 0.001, n = 51). 
Percentages of VO2max for given percentages of VO2R were all significantly higher in 
breast cancer survivors than in healthy adults (all p < 0.001, N = 52). Subgroup 
analyses for patients with and without chemotherapy revealed no significant 
differences for any value within all intensity classes (all p ≥ 0.15, n = 51 for HR, n = 
52 for VO2). 
Table 3: Values observed in breast cancer survivors at the end of primary therapy compared to the 
values for apparently healthy adults provided by the ACSM (Garber et al., 2011). 
Reference 
 
%VO2R 
Mean 
 
Healthy 
Adults 
%HRR 
Mean 
 
Cancer 
Survivors 
%HRR 
Mean ± SD 
(95% CI) 
Healthy 
Adults 
%HRmax 
Mean 
 
Cancer 
Survivors 
%HRmax 
Mean ± SD 
(95% CI) 
Cancer 
Survivors 
%APHRmax
# 
Mean ± SD 
(95% CI) 
Healthy 
Adults 
%VO2max 
Mean 
 
Cancer 
Survivors 
%VO2max 
Mean ± SD 
(95% CI) 
30 30 13.2 ± 21.5 * 57 58.8 ± 12.0 55.4 ± 12.8 37 41.5 ± 3.7 * 
  (7.1 – 19.3)   (55.4 – 62.1) (51.8 – 59.0 )  (40.5 – 42.5) 
40 40 25.8 ± 18.3 * 64 64.8 ± 10.3 61.0 ± 11.5 46 49.9 ± 3.2 * 
  (20.7 – 31.0)  (61.9 – 67.7) (57.8 – 64.2)  (49.0 – 50.7) 
60 60 51.0 ± 12.3 * 77 76.7 ± 6.9 72.2 ± 9.4 * 64 66.6 ± 2.1 * 
  (47.6 – 54.5)  (74.8 – 78.7) (69.6 – 74.9)  (66.0 – 67.2) 
90 90 88.8 ± 5.5 96 94.7 ± 2.7 * 89.1 ± 8.6 * 91 91.6 ± 0.5 * 
  (87.3 – 90.3)  (93.9 – 95.5) (86.6 – 91.5)  (91.5 – 91.8) 
Asterisks indicate significant differences (Bonferroni adjusted p < 0.017, n = 51 for HR, n = 52 for VO2, 
# compared to the ACSM’s %HRmax values for healthy adults). 
 
Training prescriptions 
A specific exercise intensity prescription table for breast cancer survivors at 
the end of primary therapy in the style of the ACSM’s table for healthy adults (Garber 
et al., 2011) but derived from the observed data is given in Table 4. This table can be 
used for exercise intensity prescription in this specific population. 
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Table 4: Exercise intensity prescriptions for breast cancer survivors at the end of primary therapy 
based on observed data in the style of the ACSM’s exercise intensity classification for apparently 
healthy adults (Garber et al., 2011) with percentages of VO2R as reference (n = 51 for HR, n = 52 for 
VO2). 
Intensity Class %VO2R %HRR %HRmax %APHRmax %VO2max %PPO 
Very light  < 30 < 13 < 59 < 55 < 42 < 25 
Light 30 - 39 13 - 25 59 - 64 55 - 60 42 - 49 25 - 35 
Moderate 40 - 59 26 - 50 65 - 76 61 - 71 50 - 66 36 - 57 
Vigorous 60 - 89 51 - 88 77 - 94 72 - 88 67 - 91 58 - 89 
Near-max. to 
maximal 
≥ 90 ≥ 89 ≥ 95 ≥ 89 ≥ 92 ≥ 90 
 
Discussion 
The present study for the first time evaluated whether and how the widely 
used ACSM’s exercise intensity classification for apparently healthy adults (Garber et 
al., 2011) needs to be adapted for breast cancer survivors at the end of primary 
therapy. This investigation is highly important because endurance training is 
recommended for breast cancer survivors due to its numerous beneficial effects 
(Hayes et al., 2009; Rock et al., 2012; Schmitz et al., 2010), but it remains unclear 
how to adequately prescribe exercise training intensities in this population. The 
analysis demonstrates that if exercise intensity in breast cancer survivors at the end 
of primary therapy is prescribed in percentages of HRR according to the ACSM’s 
intensity classification for apparently healthy adults (Garber et al., 2011), exercise is 
considerably more intense than intended. In contrast, the use of percentages of 
VO2max leads to slightly lower exercise intensities than intended. Only the use of 
percentages of HRmax according to the ACSM appears to be valid in breast cancer 
survivors within the relevant range of intensity classes. Therefore, exercise intensity 
prescriptions for healthy adults should not be uncritically adopted for breast cancer 
survivors. Especially, common prescriptions in percentages of HRR should not be 
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used. Instead, specifically adapted exercise training intensity prescriptions are 
recommended as provided in Table 4 for middle-aged breast cancer survivors at the 
end of primary therapy. 
The observed differences in intensity classes defined as percentages of HRR 
and VO2max between breast cancer survivors and healthy adults provided by the 
ACSM appear to be attributable to some differences in resting and maximal values. 
As expected (Schneider et al., 2014), mean VO2max was reduced by about 17 % 
when compared to age and sex specific reference values (Koch et al., 2009). 
However, resting oxygen uptake exactly met the standard value for healthy 
individuals of 3.5 ml∙min-1∙kg-1 (Glass & Dwyer, 2007), which together resulted in a 
reduced VO2R reflecting the smaller performance capacity in breast cancer survivors. 
Percentages of VO2R served as reference for intensity classification (Garber et al., 
2011) and the relationship between percentages of VO2R and VO2max only slightly 
differed from that in healthy individuals because of the absence of differences in 
resting oxygen uptake. In terms of percentages of HRR, the average resting heart 
rate was about 15 min-1 higher than that reported for healthy untrained females of 
similar age participating in the HERITAGE Family Study (Wilmore et al., 2001). 
Furthermore, average HRmax was about 10 min
-1 lower than expected in 52 year old 
healthy women according to a meta-analysis (Tanaka, Monahan, & Seals, 2001) 
which is not associated with a lack of spending maximal effort as indicated by the 
high RERmax. Thus, HRR was severely reduced, leading to an altered relationship 
between percentages of VO2R and HRR. 
Interestingly, there were no significant differences between breast cancer 
survivors with and without chemotherapy for any of the regressions or intensity 
classifications. This suggests that about five weeks after the end of primary therapy, 
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the relationship between the observed variables in response to incremental exercise 
is not affected in a different way from chemotherapy than from other cancer related 
factors like deconditioning due to physical inactivity, radiotherapy, targeted or 
hormone therapy. However, this finding should be interpreted cautiously. First, the 
time between the end of chemotherapy and the CPET varied between patients. They 
had received neoadjuvant or adjuvant chemotherapy regimens, and all but one of 
them had received radiation thereafter which means that the acute effects of 
chemotherapy might have already been washed out. Second, the subpopulations 
with and without chemotherapy were relatively small for statistical comparisons. 
Therefore, while the present analysis reflects a point in time typical for the beginning 
of exercise training and the sample size was sufficient for overall analyses, it may not 
be ideal to investigate the specific effects of chemotherapy on exercise intensity 
classification. 
Following the style of the ASCM’s table for exercise intensity classification for 
apparently healthy adults, we present a table for exercise intensity prescription in 
breast cancer survivors at the end of primary therapy (Table 4). This table can be 
used for training prescription in this specific population. The easiest way is to 
calculate APHRmax as 220 minus age and to prescribe aerobic activities with an 
exercise heart rate of 61–71 % APHRmax for 150 min/week (or with an exercise heart 
rate of 72–88 % APHRmax for 75 min/week). However, it should be noted that 
inaccuracies in age-predicted APHRmax may occur. Tanaka et al. (Tanaka et al., 
2001) report a range in HRmax of about 40 min
-1 in healthy women at the age of 50 
years. In the present study, measured HRmax differed from APHRmax by -42 to 19 min
-
1 (data not shown) supporting these concerns (2001). Therefore, while the use of 
APHRmax is a feasible way for exercise prescription in practice, measured instead of 
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age predicted values appear preferable in exercise intervention studies. In these 
studies, measured values ideally come from maximal CPET which is feasible and 
safe in breast cancer survivors at the end of primary therapy (Jones, Eves, 
Haykowsky, Joy, & Douglas, 2008; Lakoski et al., 2012). 
Most of the observed variables demonstrated high standard deviations for 
given percentages of VO2R, indicating individual variability in exercise intensity 
classification. In healthy individuals, points of criticism in the use of fixed percentages 
of maximal values for training prescription have been raised before. For example, 
there is considerable variation in percentages of VO2max and HRmax at the individual 
anaerobic threshold, a reference point in the blood lactate curve reflecting the 
individual metabolic situation (Meyer, Gabriel, & Kindermann, 1999). Furthermore, 
prolonged exercise at given percentages of VO2max resulted in highly variable blood 
lactate responses between individuals demonstrating an unpredictable metabolic 
exercise response (Scharhag-Rosenberger, Meyer, Gassler, Faude, & Kindermann, 
2010). Consequently, exercise prescription by means of individual thresholds, i.e. gas 
exchange or blood lactate thresholds, might be superior. In lung cancer patients, the 
ventilatory threshold has already been used for training prescription (Jones, Eves, 
Spasojevic, Wang, & Il'yasova, 2011; Jones et al., 2007). The lactate threshold has 
also been used in a population affected by different types of cancer (Dimeo, Tilmann, 
et al., 1997), but so far there are no systematic comparisons of different methods for 
exercise intensity prescription in cancer survivors. Threshold determination requires 
some additional measurements or analyses in the CPET and might therefore remain 
reserved for research. But this approach appears worth investigation to further 
improve exercise intensity prescription in cancer survivors. 
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Besides practical training prescription for breast cancer survivors, Table 4 also 
enables comparisons of pervious training studies in which different parameters were 
used to define exercise intensity. For example, in a study by Dolan et al. (2010) 
breast cancer patients initially trained for 15 min at 60 % VO2max and in a study by 
Musanti et al. (2012) they initially trained for 15–30 min at 40–65 % APHRmax. 
Comparing this by means of Table 4 or Figure 2, it is apparent that participants in the 
study by Dolan et al. (2010) trained at a moderate intensity (52 % VO2R) and the 
patients in the study by Musanti et al. (2012) trained in wide range of very light to 
moderate intensity (3–47 % VO2R). In two other studies by Vincent et al. (2013) and 
MacVicar et al. (1989) breast cancer patients initially performed interval training at 
50–60 % HRmax and 60–85 % HRR, respectively. This corresponds to the very light to 
light (15–32 % VO2R) and the vigorous intensity class (67– 87 % VO2R), 
respectively. Thus, Table 4 and Figure 2 allow converting endurance training 
intensities defined by means of different parameters into comparable intensity 
classes or % VO2R values, respectively. This for the first time enables 
comprehensive reviews and meta-analyses focusing on the effects of different 
endurance training intensities in breast cancer survivors. 
A strength of the present study is that individual linear regression equations 
were calculated for each participant instead of working with averaged data. This 
enhances accuracy of the findings. Furthermore, compared with similar analyses in 
individuals with type 2 diabetes (n = 23) (Colberg, Swain, & Vinik, 2003), obesity 
(three BMI groups with n = 22–23 in each group) (Pinet, Prud'homme, Gallant, & 
Boulay, 2008), myocardial infarction or chronic heart failure (n = 65 and n = 72, 
respectively) (Brawner, Keteyian, & Ehrman, 2002), the sample size of 52 appears 
adequate. However, there are also some weaknesses that should be addressed: A 
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relatively homogeneous group of middle-aged non-obese breast cancer survivors at 
the end of primary therapy was investigated, which limits generalizability of the data. 
The present findings might therefore be considered preliminary supporting the need 
of further studies in patients with different types of cancer and at different points in 
the cancer continuum. Another critical point is that the exercise protocol started 
relatively high at 50 W. Although the regression equations are based on a reasonable 
number 4 ± 1 (min–max: 2–6) data points, the values for very light or light exercise 
intensity classes occurred below 50 W in some instances and, therefore, the 
regression equations do not perfectly reflect these intensity classes. Furthermore, 
resting VO2 and resting HR for the calculation of VO2R and HRR were not assessed 
according to gold standard methods in the morning in a supine position after a 
defined period of rest. Instead, we used pre-exercise resting data which might be 
higher but reflect routine CPETs in a more realistic way. A previous study compared 
different methods for assessing resting values and although differences in resting 
values were observed, the relationship between percentages of VO2R and HRR was 
not affected (Cunha et al., 2010). Therefore, it is unlikely that the results of the 
present study were relevantly affected by the method of resting measurements.  
 
Conclusions 
Exercise guidelines for cancer survivors recommend 150 min/week of 
moderate or 75 min/week of vigorous aerobic exercise and suggest adaptations of 
exercise prescriptions based on the disease and treatment-related adverse effects 
(Schmitz et al., 2010). The present study for the first time quantifies the required 
adaptations for endurance training intensity prescription in middle-aged non-obese 
breast cancer survivors at the end of primary therapy. 
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Analyses of CPETs revealed that if intensity prescriptions for healthy adults 
(Garber et al., 2011) are applied in breast cancer survivors at the end of primary 
therapy, exercise prescribed in percentages of HRR is considerably more intense 
than intended. The use of percentages of VO2max results in a slightly lower intensity 
than intended and the use of HRmax appears adequate. Therefore, exercise training 
intensity prescriptions for healthy adults should not be uncritically used for cancer 
survivors. Instead, we recommend specifically adapted exercise training intensity 
prescriptions as provided here for the investigated population. Further studies in 
patients with different types of cancer and at different points in the cancer continuum 
are needed for more generalizable recommendations. 
From a scientific perspective, the variability of the observed data suggests that 
more individualized ways of intensity prescription might be superior. Future research 
should therefore address the use of ventilatory or blood lactate thresholds for 
intensity prescription in cancer survivors. 
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Abstract 
Background 
Exercise has been reported to decrease cancer-related fatigue and to increase 
quality of life (QoL) in various breast cancer populations. However, studies 
investigating exercise during radiotherapy or resistance training are scarce. We 
conducted a randomized controlled trial (BEST study) to assess the efficacy of 12-
week resistance training on fatigue beyond possible psychosocial effects of a group-
based intervention. 
Patients and methods 
One-hundred-sixty patients with breast cancer stage 0-III were randomly assigned to 
a 12-week progressive resistance training (2 times/week) or a 12-week relaxation 
control (2 times/week). Both interventions were group-based. The primary endpoint 
fatigue was assessed with a 20-item multidimensional questionnaire, QoL with 
EORTC questionnaires. Statistical analyses were based on analysis of covariance 
models for the individual changes from baseline to week 13.  
Results 
Adherence to the intervention program as well as the completion rate (97%) for the 
primary outcome variable fatigue were high. In intention-to-treat analyses for the 
N=155 patients, significant between-group mean differences (MD) favoring the 
exercise group were observed for general fatigue (P=0.044), especially for the 
subscale physical fatigue (MD= -0.8; 95% confidence interval = (-1.5, -0.2), P=0.013), 
but not for affective (P=0.91) or cognitive fatigue (P=0.65). For QoL, significantly 
larger improvements regarding the role function (P=0.035) and pain (P=0.040) were 
noted among exercisers compared to relaxation controls. Future perspective 
improved significantly stronger in the relaxation control group compared to the 
exercise group (P=0.047). 
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Conclusions 
The 12-week resistance training program was a safe, feasible and efficacious 
strategy to improve cancer-related fatigue and components of QoL in breast cancer 
patients during adjuvant radiotherapy. As exercise was compared to another group-
based intervention, results indicate that resistance training effects on fatigue and QoL 
go beyond psychosocial benefits, and that the clinically relevant overall benefit of 
resistance exercise compared to usual care can be assumed to be higher. 
Key Messages 
This randomized controlled trial evaluated the efficacy of 12-week resistance training 
beyond the psychosocial benefits associated with a 12-week group-based relaxation 
intervention on cancer-related fatigue and quality of life in 160 breast cancer patients 
receiving adjuvant radiotherapy. Between-intervention comparisons showed that the 
resistance training was an efficacious strategy to reduce the primary and clinically 
meaningful endpoint fatigue. 
Additionally uploaded online-only Supplementary Material: 
Figure S1
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Introduction 
Many breast cancer (BC) patients receive radiotherapy and are thus 
confronted with cancer-related fatigue as the most frequent side effect, with severe 
impact on quality of life (QoL) (Noal et al., 2011). Despite increasing evidence that 
exercise may be an effective treatment for fatigue, exercise during radiotherapy has 
rarely been investigated (Brown et al., 2011). To our knowledge, only one small 
randomized exercise trial (N=46) specifically investigated BC patients during 
radiotherapy (Mock et al., 1997). Four other exercise trials reported on mixed patient 
populations, including BC patients during adjuvant radiotherapy (Mock et al., 2005; 
Mustian et al., 2009; Mutrie et al., 2007; Segal et al., 2001). 
Further clarification is also needed on which types of exercise are beneficial. 
Benefits of both aerobic and resistance training on fatigue and QoL have been 
reported (Brown et al., 2011; Ohira, Schmitz, Ahmed, & Yee, 2006; Strasser, 
Steindorf, Wiskemann, & Ulrich, 2013). Yet, the majority of randomized exercise trials 
investigated pure aerobic or combined aerobic and resistance training. Thus, the 
effects of muscle strengthening exercise are still understudied (Al-Majid & Gray, 
2009). 
In addition, it is still unclear whether exercise interventions reduce fatigue and 
improve QoL primarily through psychosocial effects. It has been shown that group-
based, supervised exercise produces positive psychosocial “side effects” due to 
social interactions, improved self-efficacy, and attention from a trainer (Faller et al., 
2013), which potentially contribute to lower fatigue and higher QoL. As most previous 
studies compared exercise interventions to usual care, physiological effects beyond 
psychosocial group-related effects could not be studied. Thus, the BEST study aimed 
to evaluate the efficacy of resistance training beyond the psychosocial benefits 
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associated with a group-based non-exercise intervention on fatigue and QoL in 160 
BC patients receiving adjuvant radiotherapy. 
 
Methods 
Study design 
The BEST study is a prospective, randomized, controlled intervention trial 
evaluating a 12-week resistance training in stage 0-III BC patients during adjuvant 
radiotherapy. To determine the effect of exercise per se, the control group received a 
supervised group-based muscle-relaxation program. Both interventions began 
parallel to the first radiotherapy. Endpoints were assessed before start of 
radiotherapy (baseline, T0), post-radiotherapy (week 7, T1), and post-intervention 
(week 13, T2). The study was approved by the ethics committee of the University of 
Heidelberg and registered at ClinicalTrials.gov (NCT01468766). Details of the study 
design are described elsewhere (Potthoff et al., 2013). 
 
Patients 
Eligibility criteria were: histologically confirmed primary BC; stage 0-III after 
lumpectomy or mastectomy; scheduled for radiotherapy; age ≥18 years; body mass 
index (BMI) ≥18 kg/m2; ability to understand and follow the study protocol; and 
willingness to come to the exercise facilities. Patients with contraindications for 
resistance training (e.g., acute infectious disease, severe cardiac disease, severe 
respiratory insufficiency), patients with other concomitant malignant diseases (except 
carcinoma in situ of skin or cervix), and patients who were currently participating in 
systematic intense exercise training (at least 1h twice/week) or who had previously 
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participated in an exercise intervention trial were excluded on screening. All 
participants gave written informed consent. 
 
Recruitment and randomization 
Eligible patients scheduled for adjuvant radiotherapy at the University of 
Heidelberg Medical Center between February 2011 and March 2013 were contacted 
in clinic. Interested patients were informed in detail by the BEST study physicians 
and study coordinators. Patients who signed the written informed consent underwent, 
within 21 days prior to the start of radiation, a baseline assessment at the National 
Center for Tumor Diseases (NCT), including a check for contraindications. Eligible 
participants were randomly allocated 1:1 to the exercise group (EX) or relaxation 
control group (RC). Allocation was done by a biometrician who was not involved in 
the recruitment procedure, based on predetermined lists with random block size, 
stratified by age and baseline physical fatigue level. Study personnel did not have 
access to the randomization lists.  
 
Interventions 
Both interventions were administered for about 60 minutes twice weekly over a 
12-week period together with other cancer patients under the supervision of trained 
and experienced physiotherapists in specific training facilities at the study center. The 
intervention started at the day of the first radiotherapy treatment. Physical status, 
adverse events and adherence were recorded for each training session by the 
participants and the trainers. The progressive exercise intervention comprised 8 
different machine-based resistance exercises (3 sets, 8-12 repetitions at 60–80% of 
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1-RM) (Potthoff et al., 2013). The control group performed progressive muscle 
relaxation without any aerobic or muscle strengthening components. 
 
Outcome measures 
The primary endpoint was change of cancer-related fatigue from baseline to 
week 13. Fatigue was assessed with the Fatigue Assessment Questionnaire (FAQ), 
a 20-item, self-assessment questionnaire validated for a German-speaking 
population (Glaus & Muller, 2001). It covers the physical, affective and cognitive 
fatigue dimensions. Scores are on a 0-100 scale, with higher scores indicating worse 
fatigue.  
Quality of life (QoL) was assessed with the validated, 30-item self-assessment 
questionnaire of the European Organisation for Research and Treatment of Cancer 
(EORTC QLQ-C30, version 3.0) (Aaronson et al., 1993). In addition, the 23-item BC-
specific EORTC QLQ-BR23 was applied.  
Depressive symptoms were self-assessed with the 20-item CES-D scale, a 
validated instrument for cancer patients (Schroevers, Sanderman, van Sonderen, & 
Ranchor, 2000). Cognitive function was estimated with the trail-making-test, a reliable 
and valid measure used in neuropsychological diagnostics (Sanchez-Cubillo et al., 
2009). 
Muscle strength was measured for isometric and isokinetic muscle capacity of 
representative muscle groups for upper and lower extremity (Potthoff et al., 2013). 
Endurance performance (VO2peak) was measured on a bicycle ergometer. The 
procedure was also used to identify exercise-contraindicating cardiac impairments. 
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Safety 
Potential adverse effects (e.g., lymphedema, pain, muscle soreness, nausea, 
dyspnea, tachycardia) were recorded by the participants at each training session, 
using standardized questionnaires. Adverse events reported spontaneously by the 
patient or observed by therapists were also recorded. 
 
Sample size and statistical analyses 
The study was designed to detect a standardized effect size of 0.5 for total 
fatigue with a two-sided t-test of power of 80% at 5% significance level. Thus, 64 
patients per arm were needed for analysis. Assuming a maximal drop-out rate of 
20%, 80 patients were recruited per arm. 
Data were analyzed on the intent-to-treat-basis (ITT). Analysis of covariance 
(ANCOVA) was used with pre- to post-intervention change as dependent variable, 
the intervention group as independent variable, and the baseline measure as 
covariate. To fulfill the normality assumption, fatigue parameters were square-root 
transformed. Transformation of EORTC parameters was not needed. As the number 
of missing fatigue values was very low (3%), we performed complete-case analyses. 
Confounding and effect modification by potential influencing factors, such as age, 
baseline BMI, and treatment characteristics, were investigated. Further sensitivity 
analyses were performed, using ordinal logistic regression, to investigate robustness 
of results for the EORTC symptoms that are based only on single items. Results did 
not differ substantially from the ANCOVA results. We made no adjustment for 
multiple comparisons for the secondary outcomes, which were considered to be 
explorative analyses. 
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Figure 1. CONSORT diagram 
Abbreviations: FAQ, Fatigue Assessment Questionnaire; T0, before start of radiotherapy and 
intervention (baseline); T1, post radiotherapy (week 7); T2, post intervention (week 13) 
 
Standardized effect sizes (ES) were calculated for all outcomes by dividing the 
between-group difference of the post-intervention means (adjusted for baseline 
values) by the pooled baseline standard deviation. For ease of presentation, ES in 
favor of EX received a positive sign and in favor of RC a negative sign. All statistical 
tests were two-sided, and P<0.05 was considered statistically significant. SAS 
Version 9.3 was used for all analyses. 
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Results 
A total of 321 BC patients were personally informed about the study, 170 gave 
written informed consent and underwent baseline diagnostics, out of which 160 
patients were randomized for the BEST study, 80 to EX and 80 to RC (Figure 1). Pre- 
and post-intervention assessment of the primary endpoint was available in a total of 
155 (97%) participants, 77 in EX and 78 in RC. Demographics and treatment 
characteristics did not differ significantly between both intervention groups (Table 1). 
Mean age was 56 years (range 29-75). The majority of patients had not received any 
chemotherapy before radiotherapy (64%). Neo-adjuvant chemotherapy had been 
completed by 19% of the patients (median time to baseline: 9 weeks, 1st to 3rd 
quartile range (QR): 8-11 weeks). The other patients (16%) had completed adjuvant 
chemotherapy shortly before baseline (median: 3.5 weeks, QR: 2.7–5.0). All primary 
and secondary outcome variables were equally distributed in EX and RC at baseline 
(all P>0.05), except for the EORTC symptom dry mouth (P=0.033). 
Table 1: Baseline Characteristics of the Study Population 
Characteristics  TOTAL 
(n=155)    
 Exercise 
(n=77)  
 Control (n=78)  
  No. % No. % No. % 
Age, years 
Mean   55.8 55.2 56.4 
SD  9.1 9.5 8.7 
BMI 
Mean   27.2 26.9 27.6 
SD  5.1 5.4 4.8 
Days since surgery 
Mean   67.1 68.1 66.2 
SD  56.0 60.7 51.1 
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Table 1: Baseline Characteristics of the Study Population 
Characteristics  TOTAL 
(n=155)    
 Exercise 
(n=77)  
 Control (n=78)  
Stage 
0  14 9.0 9 11.7 5 6.4 
1  81 52.3 36 46.8 45 57.7 
2  45 29.0 27 35.1 18 23.0 
3  15 9.6 5 6.5 10 12.8 
Pre-treatment 
Neo-adjuvant 
chemotherapy 
 30 19.4 14 18.2 16 20.5 
Surgery only  100 64.5 51 66.2 49 62.8 
Adjuvant chemotherapy  25 16.1 12 15.6 13 16.7 
Radiation technic 
3D  116 74.8 61 79.2 55 70.5 
IMRT  39 25.2 16 20.8 23 29.5 
Radiation boost  113 72.9 57 74.0 56 71.8 
Current herceptin therapy  11 7.1 7 9.1 4 5.1 
Current hormone therapy  75 48.4 41 53.2 34 43.6 
Sports in the year before diagnosis 
none  66 42.6 33 42.9 33 42.3 
>0-9 MET*h/wk  38 24.5 19 24.7 19 24.4 
>9-21 MET*h/wk  27 17.4 15 19.5 12 15.4 
>21 MET*h/wk  24 15.5 10 13.0 14 17.9 
Current smokers  16 10.3 9 11.7 7 9.0 
Abbreviations: BMI, Body Mass Index; IMRT, Intensity Modulated Radiation Therapy; MET, metabolic 
equivalent; SD, standard deviation. 
 
Adherence was similar in both groups. Out of 24 scheduled sessions, the 
median attended number was 19 (QR: 13–23, range 1-24) in EX and 19 (QR: 12–22, 
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range 0-24) in RC. In EX, significant improvements were observed for muscle 
strength, e.g., in isokinetic knee flexion (P<0.0001), but not for cardiorespiratory 
fitness. No injuries or severe adverse events related to the interventions were 
reported. The frequency of reported lymphedema did not differ between groups. 
 
Primary endpoint 
Overall, from pre- to post-intervention, total cancer-related fatigue decreased 
significantly in EX, while in RC there was no significant change (Table 2). 
Correspondingly, the primary ITT analysis showed significant differences between 
both intervention groups (P=0.044) with ES=0.25 (Figure S1). Considering the 
different fatigue dimensions, the effect was significant regarding physical fatigue 
(P=0.013, ES=0.33), but not for the affective (P=0.91, ES=0.01) or the cognitive 
(P=0.65, ES=0.07) dimension. 
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Table 2: Fatigue at different timepoints, adjusted mean changes and between-group differences 
   Mean (SD)  Adjusted‡ Mean Change (95%CI)  Adjusted‡ Between-Group Difference (95%CI) 
Outcome* Arm N† Baseline 
(T0) 
Post RT 
(T1) 
Post Interv. 
(T2) 
 
from T0 to T1 from T1 to T2 from T0 to T2  from T0 to T1 from T1 to T2 from T0 to T2 
Overall 
Total fatigue Exercise 77 5.9 (2.2) 5.9 (2.0) 5.4 (2.3)  0.0 (-0.3, 0.4) -0.6 (-0.9, -0.3) -0.5 (-0.9, -0.2)  -0.4 (-0.9, 0.1) -0.1 (-0.5, 0.3) -0.5 (-1.0, -0.0) 
 Relaxation 78 6.0 (2.0) 6.3 (1.7) 5.9 (1.9)  0.4 (0.1, 0.8) -0.5 (-0.8, -0.2) -0.0 (-0.4, 0.3)     
       
Physical fatigue Exercise 77 5.7 (2.7) 6.1 (2.2) 5.0 (2.8)  0.4 (-0.0, 0.8) -1.1 (-1.5, -0.7) -0.7 (-1.2, -0.3)  -0.3 (-0.9, 0.3) -0.5 (-1.1, 0.1) -0.8 (-1.5, -0.2) 
 Relaxation 78 5.9 (2.3) 6.4 (2.0) 5.9 (2.2)  0.7 (0.2, 1.1) -0.6 (-1.0, -0.2) 0.1 (-0.4, 0.6)     
       
Affective fatigue Exercise 77 5.8 (2.7) 5.4 (2.7) 5.3 (2.6)  -0.4 (-0.8, 0.1) -0.0 (-0.4, 0.4) -0.5 (-1.0, -0.0)  -0.3 (-0.9, 0.4) 0.3 (-0.3, 0.9) -0.0 (-0.7, 0.6) 
 Relaxation 78 5.6 (2.5) 5.4 (2.5) 5.2 (2.6)  -0.1 (-0.6, 0.3) -0.3 (-0.8, 0.1) -0.5 (-0.9, 0.0)     
       
Cognitive fatigue Exercise 77 4.9 (3.0) 4.9 (3.0) 4.9 (3.2)  -0.1 (-0.6, 0.4) -0.2 (-0.7, 0.4) -0.1 (-0.8, 0.5)  -0.8 (-1.5, -0.1) 0.4 (-0.4, 1.2) -0.2 (-1.1, 0.7) 
 Relaxation 78 5.4 (3.1) 5.9 (2.6) 5.3 (3.0)  0.7 (0.2, 1.2) -0.6 (-1.1, -0.0) 0.1 (-0.6, 0.7)     
Patients with Preceding Adjuvant Chemotherapy 
Total fatigue Exercise 12 7.0 (1.2) 5.2 (2.0) 5.3 (2.1)  -1.7 (-2.6, -0.8) 0.0 (-0.5, 0.6) -1.6 (-2.4, -0.8)  -1.0 (-2.3, 0.2) 0.2 (-0.6, 0.9) -0.8 (-1.9, 0.3) 
 Relaxation 13 6.4 (2.2) 5.9 (1.6) 5.7 (1.4)  -0.6 (-1.5, 0.2) -0.1 (-0.7, 0.4) -0.8 (-1.6, -0.0)     
       
Physical fatigue Exercise 12 7.7 (1.5) 5.2 (2.4) 4.8 (2.7)  -2.2 (-3.4, -1.1) -0.5 (-1.2, 0.2) -2.7 (-3.8, -1.7)  -1.3 (-2.9, 0.3) -0.3 (-1.3, 0.7) -1.5 (-3.1, -0.0) 
 Relaxation 13 6.6 (2.7) 5.9 (1.9) 5.6 (1.7)  -1.0 (-2.1, 0.1) -0.2 (-0.9, 0.5) -1.2 (-2.2, -0.2)     
       
Affective fatigue Exercise 12 5.5 (2.7) 4.6 (2.7) 5.2 (2.7)  -0.9 (-2.2, 0.3) 0.6 (-0.2, 1.3) -0.3 (-1.6, 1.0)  -0.7 (-2.5, 1.0) 0.8 (-0.3, 1.8) 0.2 (-1.6, 1.9) 
 Relaxation 13 5.5 (2.6) 5.3 (2.6) 5.1 (2.2)  -0.2 (-1.4, 1.0) -0.2 (-0.9, 0.5) -0.4 (-1.7, 0.8)     
       
Cognitive fatigue Exercise 12 4.9 (2.7) 3.7 (3.2) 4.9 (2.9)  -1.3 (-2.4, -0.2) 0.7 (-0.7, 2.1) -0.5 (-2.0, 1.1)  -0.7 (-2.3, 0.8) 0.4 (-1.6, 2.4) -0.1 (-2.3, 2.1) 
 Relaxation 13 6.1 (2.3) 5.4 (2.0) 5.4 (2.3)  -0.6 (-1.6, 0.5) 0.3 (-1.0, 1.7) -0.4 (-1.8, 1.1)     
Patients without Preceding Adjuvant Chemotherapy 
Total fatigue Exercise 65 5.7 (2.3) 6.1 (2.0) 5.4 (2.3)  0.4 (0.0, 0.7) -0.7 (-1.0, -0.3) -0.3 (-0.7, 0.0)  -0.3 (-0.8, 0.2) -0.1 (-0.6, 0.4) -0.5 (-1.0, 0.1) 
 Relaxation 65 5.9 (1.9) 6.4 (1.7) 6.0 (2.0)  0.7 (0.3, 1.0) -0.5 (-0.9, -0.2) 0.1 (-0.3, 0.5)     
       
Physical fatigue Exercise 65 5.4 (2.8) 6.3 (2.2) 5.1 (2.9)  0.8 (0.4, 1.3) -1.2 (-1.7, -0.7) -0.4 (-0.9, 0.1)  -0.2 (-0.8, 0.5) -0.5 (-1.2, 0.2) -0.7 (-1.4, 0.0) 
 Relaxation 65 5.7 (2.3) 6.5 (2.0) 6.0 (2.3)  1.0 (0.6, 1.5) -0.7 (-1.2, -0.2) 0.3 (-0.2, 0.8)     
       
Affective fatigue Exercise 65 5.9 (2.7) 5.5 (2.7) 5.3 (2.6)  -0.3 (-0.8, 0.2) -0.2 (-0.6, 0.3) -0.5 (-1.0, -0.0)  -0.2 (-0.9, 0.6) 0.2 (-0.4, 0.9) -0.1 (-0.8, 0.6) 
 Relaxation 65 5.7 (2.5) 5.5 (2.5) 5.3 (2.7)  -0.1 (-0.6, 0.4) -0.4 (-0.9, 0.1) -0.5 (-1.0, 0.1)     
       
Cognitive fatigue Exercise 65 4.9 (3.1) 5.1 (3.0) 4.9 (3.3)  0.1 (-0.4, 0.7) -0.4 (-1.0, 0.2) -0.1 (-0.8, 0.6)  -0.8 (-1.6, 0.0) 0.4 (-0.5, 1.2) -0.3 (-1.2, 0.7) 
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   Mean (SD)  Adjusted‡ Mean Change (95%CI)  Adjusted‡ Between-Group Difference (95%CI) 
Outcome* Arm N† Baseline 
(T0) 
Post RT 
(T1) 
Post Interv. 
(T2) 
 
from T0 to T1 from T1 to T2 from T0 to T2  from T0 to T1 from T1 to T2 from T0 to T2 
 Relaxation 65 5.2 (3.2) 6.0 (2.8) 5.3 (3.1)  0.9 (0.4, 1.5) -0.8 (-1.4, -0.1) 0.1 (-0.5, 0.8)     
Abbreviations: CI, confidence interval; Interv., Intervention; RT, radio therapy; SD, standard deviation. 
* Fatigue scores were square-root transformed from the original 0-100 score to reach a good model fit, thus resulting in a 0-10 scale. 
† Number of patients with measures at both timepoints, T0 and T2. ‡ Regression models are adjusted for baseline value. 
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Secondary endpoints 
Investigation of the EORTC QoL scores (Table 3, Figure S1) revealed a 
significant increase in global QoL in EX from pre- to post-intervention but no 
significant change in RC, but the between-group difference was small and 
nonsignificant (P=0.37, ES=0.15). Significantly larger improvements in EX vs. RC 
were detected in role function (P=0.035, ES=0.31) and in pain (P=0.040, ES=0.25). 
Future perspective improved significantly more in RC compared to EX (P=0.047, 
ES=0.28). Emotional function, social function, and body image improved significantly 
in both intervention groups, without a significant between-group difference. 
Further, small effects in favor of EX were observed for several QoL symptoms. 
However, these effects failed to reach statistical significance (Table 3). Regarding the 
CES-D depression score, there was no significant change from pre- to post-
intervention in either of the intervention groups (Table 3, Figure S1). Overall cognitive 
performance improved slightly more in EX than in RC, but between-group differences 
were nonsignificant. 
The results remained stable when adjusting the ANCOVA models for 
randomization strata or other potential influencing factors, such as age, previous 
chemotherapy, baseline BMI, baseline depression, sports in the year before 
diagnosis, or living status (alone/with others). No significant interactions were 
observed. 
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Table 3: Patient Reported Outcomes Pre-/Post-Intervention, Adjusted Mean Changes and Between-Group 
Differences 
               Mean (SD)                  .        
Adjusted‡ Mean  
Change (95% CI)   
Adjusted‡ Between-Group 
  Difference (95% CI)  
Outcome* Arm N† Baseline 
(T0) 
Post Intervention 
(T2) 
from T0 to T2 from T0 to T2 p  
Global QoL Exercise 76 59.3 (21.3) 64.3 (24.5) 4.6 (0.1, 9.2) 3.0 (-3.5, 9.5) 0.37 
 Relaxation 72 60.8 (20.0) 62.0 (21.2) 1.6 (-3.1, 6.3)   
Quality of life - EORTC QLQ30 functions (Scale 0-100)  
Physical function Exercise 77 80.5 (18.0) 82.5 (18.8) 2.2 (-0.8, 5.2) 1.5 (-2.7, 5.7) 0.48 
 Relaxation 78 79.1 (16.7) 80.0 (16.9) 0.7 (-2.3, 3.7)   
 
Emotional function Exercise 77 58.4 (23.7) 65.5 (25.5) 7.2 (3.0, 11.5) -2.2 (-8.1, 3.8) 0.48 
 Relaxation 78 57.3 (25.7) 66.9 (23.9) 9.4 (5.2, 13.6)   
 
Role function Exercise 75 63.6 (27.9) 75.3 (28.3) 11.2 (5.7, 16.7) 8.5 (0.6, 16.3) 0.035 
 Relaxation 71 66.0 (27.4) 68.1 (26.8) 2.7 (-2.9, 8.3)   
 
Cognitive function Exercise 77 72.9 (27.2) 75.5 (27.3) 3.2 (-1.5, 7.8) 4.2 (-2.4, 10.8) 0.21 
 Relaxation 76 69.7 (27.6) 69.3 (26.8) -1.0 (-5.7, 3.7)   
 
Social function Exercise 75 68.4 (30.7) 75.6 (27.2) 8.0 (3.4, 12.7) -0.8 (-7.4, 5.7) 0.81 
 Relaxation 75 64.7 (29.2) 74.4 (23.5) 8.9 (4.2, 13.5)   
 
Quality of life - EORTC QLQ30 symptoms (Scale 0-100)  
        
Fatigue Exercise 77 42.4 (24.9) 34.3 (28.1) -8.1 (-13.0, -3.3) -5.9 (-12.7, 0.9) 0.09 
 Relaxation 77 43.1 (26.3) 40.7 (25.1) -2.2 (-7.1, 2.6)   
 
Insomnia Exercise 76 39.0 (30.0) 39.0 (30.0) -1.8 (-8.2, 4.5) -8.8 (-17.8, 0.2) 0.05 
 Relaxation 77 46.3 (36.3) 51.5 (34.9) 7.0 (0.7, 13.3)   
 
Dyspnea Exercise 77 27.7 (30.3) 25.1 (29.7) -2.9 (-9.0, 3.2) -6.7 (-15.3, 1.9) 0.13 
 Relaxation 77 29.0 (34.3) 32.5 (33.8) 3.8 (-2.3, 9.9)   
 
Nausea  Exercise 76 5.7 (15.0) 5.3 (13.7) -1.4 (-4.7, 1.9) 0.1 (-4.5, 4.8) 0.96 
and vomiting Relaxation 77 7.8 (20.2) 5.4 (15.6) -1.5 (-4.8, 1.8)   
 
Pain Exercise 77 29.4 (30.2) 25.5 (26.4) -4.0 (-8.9, 1.0) -7.4 (-14.4, -0.3) 0.040 
 Relaxation 75 29.8 (29.4) 33.1 (31.5) 3.4 (-1.6, 8.4)   
 
Appetite loss Exercise 77 13.0 (23.7) 7.8 (18.7) -4.7 (-9.0, -0.3) -5.0 (-11.1, 1.1) 0.11 
 Relaxation 77 11.3 (23.3) 12.1 (23.5) 0.3 (-4.0, 4.7)   
 
Constipation Exercise 77 7.8 (17.0) 5.6 (16.6) -3.0 (-7.5, 1.6) -3.4 (-9.8, 3.1) 0.30 
 Relaxation 77 11.7 (23.4) 11.3 (28.4) 0.4 (-4.1, 4.9)   
 
Diarrhea Exercise 77 8.7 (20.5) 7.4 (15.9) -1.4 (-6.0, 3.1) -4.6 (-11.1, 1.8) 0.16 
 Relaxation 77 9.1 (24.0) 12.1 (25.9) 3.2 (-1.4, 7.7)   
 
Financial difficulties Exercise 77 23.8 (31.0) 23.4 (29.6) -0.0 (-4.8, 4.8) -1.8 (-8.6, 5.0) 0.60 
 Relaxation 76 21.5 (33.4) 23.7 (29.7) 1.8 (-3.1, 6.6)   
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               Mean (SD)                  .        
Adjusted‡ Mean  
Change (95% CI)   
Adjusted‡ Between-Group 
  Difference (95% CI)  
Outcome* Arm N† Baseline 
(T0) 
Post Intervention 
(T2) 
from T0 to T2 from T0 to T2 p  
Quality of life - EORTC BR23 functions (Scale 0-100)  
Future perspective Exercise 71 38.0 (29.4) 49.8 (34.2) 11.2 (5.4, 16.9) -8.4 (-16.6, -0.1) 0.047 
 Relaxation 67 41.3 (30.2) 60.2 (26.7) 19.5 (13.6, 25.4)   
 
Body Image Exercise 71 68.2 (32.1) 76.2 (27.7) 7.3 (3.4, 11.1) 0.2 (-5.4, 5.8) 0.95 
 Relaxation 67 72.9 (28.5) 79.2 (25.8) 7.1 (3.1, 11.1)   
 
Sexual functioning Exercise 69 33.5 (31.8) 42.8 (32.0) 10.3 (4.9, 15.6) 7.4 (-0.4, 15.2) 0.063 
and satisfaction Relaxation 62 27.6 (29.7) 31.5 (28.8) 2.8 (-2.8, 8.5)   
 
Quality of life - EORTC BR23 symptoms (Scale 0-100)  
Side effects  Exercise 71 26.8 (19.3) 26.8 (20.0) -0.8 (-4.4, 2.7) 1.5 (-3.6, 6.6) 0.56 
(overall) Relaxation 67 30.8 (21.7) 27.5 (17.5) -2.3 (-6.0, 1.3)   
 
Feeling sick Relaxation 68 35.8 (26.6) 25.5 (29.4) -9.8 (-15.6, -4.0) -4.7 (-13.0, 3.6) 0.26 
 Exercise 66 33.3 (28.0) 28.8 (28.6) -5.1 (-11.0, 0.8)   
 
Dry mouth Exercise 77 22.9 (30.7)+ 21.2 (31.5) -3.4 (-9.4, 2.7) -3.7 (-12.3, 4.8) 0.3883 
 Relaxation 78 31.2 (31.0) 29.9 (33.4) 0.4 (-5.6, 6.4)   
 
Taste disorders Relaxation 77 16.9 (29.9) 17.3 (29.4) -0.6 (-5.7, 4.4) 6.9 (-0.2, 14.0) 0.058 
 Exercise 78 20.5 (31.9) 12.0 (22.1) -7.5 (-12.5, -2.5)   
 
Eye symptoms Exercise 77 26.4 (31.2) 27.3 (31.9) -0.3 (-6.2, 5.6) 4.1 (-4.2, 12.4) 0.33 
 Relaxation 78 30.8 (35.9) 25.2 (29.0) -4.4 (-10.3, 1.4)   
 
Hair loss/upset Relaxation 74 14.4 (29.2) 15.8 (26.6) -1.9 (-7.3, 3.5) 7.2 (-0.4, 14.9) 0.062 
 Exercise 76 22.8 (37.0) 10.5 (22.6) -9.1 (-14.5, -3.8)   
 
Hot flashs Exercise 71 47.4 (35.9) 54.5 (34.4) 7.4 (0.2, 14.7) -3.8 (-14.2, 6.7) 0.48 
 Relaxation 66 46.0 (37.8) 57.6 (35.3) 11.2 (3.7, 18.7)   
 
Head ache Relaxation 70 19.0 (26.4) 22.4 (30.9) 3.0 (-2.6, 8.6) -1.5 (-9.5, 6.6) 0.72 
 Exercise 66 21.7 (25.8) 25.8 (29.1) 4.4 (-1.3, 10.2)   
 
Arm symptoms Exercise 74 26.3 (25.5) 22.7 (25.4) -3.0 (-7.6, 1.5) -0.7 (-7.0, 5.7) 0.83 
 Relaxation 78 23.6 (24.4) 21.8 (23.3) -2.3 (-6.8, 2.1)   
 
Breast symptoms Relaxation 74 27.7 (22.5) 27.0 (21.2) -0.4 (-5.0, 4.1) -6.1 (-12.4, 0.3) 0.061 
 Exercise 78 26.7 (21.0) 32.6 (23.4) 5.6 (1.2, 10.0)   
 
Depression - CES-D (Scale 0-100)  
Depression score Exercise 75 26.1 (16.8) 24.6 (17.7) -1.6 (-4.4, 1.1) 0.7 (-3.1, 4.6) 0.71 
 Relaxation 76 27.5 (17.2) 25.0 (16.6) -2.4 (-5.1, 0.4)   
 
Cognitive function - Trail-Making-Test [seconds]  
Overall Exercise 72 112.9 (45.5) 98.3 (36.9) -15.0 (-19.9,-
10.0) 
-5.4 (-12.3, 1.5) 0.13 
performance Relaxation 73 116.0 (45.2) 106.0 (42.7) -9.6 (-14.4, -4.7)   
 
Executive  Exercise 72 77.9 (34.8) 66.9 (28.8) -11.5 (-15.4, -7.5) -3.7 (-9.2, 1.9) 0.19 
functioning Relaxation 73 81.3 (35.8) 72.9 (30.2) -7.8 (-11.7, -3.9)   
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               Mean (SD)                  .        
Adjusted‡ Mean  
Change (95% CI)   
Adjusted‡ Between-Group 
  Difference (95% CI)  
Outcome* Arm N† Baseline 
(T0) 
Post Intervention 
(T2) 
from T0 to T2 from T0 to T2 p  
 
Cognitive  Exercise 72 35.0 (13.9) 31.4 (11.1) -3.6 (-5.8, -1.4) -1.9 (-5.0, 1.1) 0.22 
processing speed Relaxation 73 34.7 (12.0) 33.1 (14.2) -1.7 (-3.8, 0.5)   
Abbreviations: CI, confidence interval; CES-D, Center of Diseases Depression Scale; QoL, Quality of Life; SD, standard 
deviation. 
*   Fatigue scores square-root transformed, i.e. scale 0-10. 
†  Number of patients with measures at both timepoints, T0 and T2. 
‡  Regression models are adjusted for baseline value. 
+  Difference between both intervention groups at baseline, p < 0.05. 
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Figure S1. Effect sizes for fatigue, quality of life, depression and cognition 
Effect sizes (ES), denoted by a dot, with 95% confidence intervals, for the difference between the resistance 
exercise intervention group and the relaxation control group, based on changes from baseline to the end of 
intervention (week 13) and adjusted for baseline scores. For ease of presentation, the results for some items were 
rescaled so that now all ES in favor of the resistance training received a positive sign, and in favor of relaxation a 
negative sign. Estimates expressed in units of 1 standard deviation. 
Abbreviations: FAQ, Fatigue Assessment Questionnaire; EORTC, European Organisation for Research and 
Treatment of Cancer; QoL, quality of life; HRQoL, health-related quality of life; QLQ30, 30-item questionnaire for 
QoL; BR23, 23-item breast cancer specific questionnaire; CES-D, 20-item depression scale. 
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Discussion 
We report here the results of a large randomized controlled trial in BC patients 
testing the effects of exercise during adjuvant radiotherapy. The 12-week resistance 
exercise program was an efficacious strategy to reduce the primary endpoint total 
fatigue, particularly physical fatigue. Furthermore, improvements in some subscales 
of QoL were observed. The program was safe and had good adherence. Since 
group-based relaxation training was chosen as the control group, our results indicate 
that resistance exercise provides beneficial effects beyond psychosocial effects 
induced by group-based programs. 
Several studies have investigated the effect of exercise on fatigue in BC 
patients. A meta-analysis including 25 randomized exercise intervention trials 
reported an overall effect size of 0.39 (95% CI: 0.27-0.51) (Brown et al., 2011). Our 
study adds to current knowledge for BC patients with respect to two understudied 
areas: (1) exercise was performed during radiotherapy; and (2) the type of training 
was pure resistance exercise. So far, only three randomized studies analyzed 
resistance exercise interventions without aerobic components with respect to fatigue 
or QoL (Courneya et al., 2007; Ohira et al., 2006; Winters-Stone et al., 2012). One 
study (Courneya et al., 2007) randomly assigned 242 patients receiving 
chemotherapy to resistance exercise, aerobic exercise, or usual care, but did not 
observe significant effects, possibly due to the high variability of outcomes during 
chemotherapy. Another study (Winters-Stone et al., 2012) also reported no difference 
in fatigue among 106 postmenopausal survivors randomized to a 1-year resistance 
exercise or stretching program. Yet results were limited by a nonrandom drop-out 
rate of 37%. The third study (Ohira et al., 2006) did not investigate fatigue, but 
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observed significant improvements in the physical and the psychosocial QoL score 
among 86 survivors randomized to resistance training compared to usual care. 
We chose a group-based control intervention with psychosocial conditions 
similar to the exercise program and for which beneficial effects on fatigue were 
shown (Song, Xu, Zhang, Ma, & Zhao, 2013) Thus, our observed effects for 
resistance training likely refer to physiological effects of exercise, over and above the 
psychosocial benefits associated with group-based programs. The clinically relevant 
overall effect of resistance exercise compared to usual care can therefore be 
expected to be higher than the one observed in our study. 
For general QoL, our observed ES of 0.15 was smaller than the ES of 0.34 
(95% CI: 0.07-0.62) reported by a meta-analysis on randomized exercise studies in 
BC patients during adjuvant therapy (Carayol et al., 2013), presumably due to 
choosing an active control group in our study with psychosocial benefits too. Our 
analyses regarding QoL functions and symptoms suggest that resistance training 
also has physiological effects on QoL. Compared to RC there were improvements in 
role function and pain. The benefit regarding pain is especially relevant, because 
patients and physicians are often concerned that intense resistance exercise may 
increase side effects. On the other hand, patients in the relaxation group were less 
concerned about the future, reflecting rather psychological aspects. Although we did 
not correct for multiple testing so that some findings might have appeared by chance, 
our results strengthen observations from a Cochrane review that exercise has 
beneficial effects on QoL (Mishra et al., 2012). It is not surprising that no differences 
in emotional and social functions between EX and RC were found, because 
psychosocial interventions, including relaxation programs, may also have beneficial 
effects on emotional distress (Faller et al., 2013). Accordingly, while previous 
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randomized intervention trials reported reduced depression in exercise programs 
compared to usual care (Daley et al., 2007), we did not observe benefits of EX over 
RC regarding depression. 
In conclusion, our large randomized controlled intervention trial indicates that 
resistance exercise is safe, feasible as well as efficacious in improving cancer-related 
fatigue and components of QoL in BC patients during adjuvant radiotherapy. With 
fatigue being the most frequent side effect during radiotherapy, this finding is 
clinically meaningful to many BC patients. The observed physiological effects of 
resistance exercise are over and above psychosocial benefits associated with group-
based supervised programs. Our results substantiate the claim that resistance 
training should become an integral part of exercise prescriptions for BC patients and 
that these programs should begin parallel to adjuvant radiotherapy. 
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8. General discussion 
8.1. Summarizing the main findings 
Gold standard fitness measuring methods showed markedly impaired physical 
performance level in breast cancer patients and the need of adjustment of the 
intensity prescription during treatment. In addition physical exercise, particularly 
strength training plays an important role in cancer prevention as well as in the 
prevention and treatment of cancer-related fatigue during. This chapter summarizes 
the main results, and considers remaining problems with the quality of the studies. 
Afterward, it discusses the main findings in light of the existing literature and ends 
with concluding remarks, implications, and suggestions for future research. 
 
Cardiorespiratory fitness in breast cancer patients undergoing adjuvant 
therapy (I. Publication) 
The cardiorespiratory fitness analyses of 222 breast cancer patients clearly 
show that their marked and significantly impaired cardiopulmonary function with 
mean VO2peak was 20.6 ± 6.7 ml/min/kg, compared to the expected mean VO2peak of 
24.3 ± 5.5 ml/min/kg among a healthy population of comparable age and BMI 
distribution. An even lower adjusted mean VO2peak was measured among patients 
post adjuvant chemotherapy, compared to patients with no chemotherapy or who had 
just started chemotherapy, with 63% of the expected level. The impact on VO2peak 
appears to accumulate over the course of chemotherapy, while heart rate was 
already impaired during the first chemotherapy cycles. However, there was no 
significant association between chemotherapy treatment and ventilatory threshold. 
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Chemotherapy seems to impair cardiorespiratory fitness by influencing the oxygen 
delivery system, rather than impacting metabolic muscle function. 
 
What this study adds 
 These results contribute to gold standard measurements of cardiorespiratory 
fitness with breast cancer patients in acute cancer treatment. 
 Breast cancer patients showed markedly impaired physical performance level 
after CT. 
 The significant performance differences between CT and non-CT treatment 
groups underline the need for individual exercise therapy in breast cancer patients 
as early as possible to prevent or counteract the loss of physical performance 
during the anti-cancer therapy. 
 
Muscular strength in breast cancer patients undergoing adjuvant therapy (II. 
Publication) 
Testing with the isokinetic device was safe and practical. The analysis of 255 
breast cancer patients shows that strength and muscular fatigue (the fatigue index 
was up to 50% higher) are strongly mediated by chemotherapy and are most 
impaired, with up to 25% in the lower extremities, in patients undergoing 
chemotherapy. On average, all of the patient groups, including those who had just 
started chemotherapy and those who only had breast cancer surgery, had a 
significantly impaired physical performance status compared with healthy controls. 
The strength of the upper extremities was no different between breast cancer patient 
groups, but the type of surgery was associated with 12% less flexibility in the 
shoulder after a radical mastectomy than after a partial mastectomy. The reason for 
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dysfunctions in upper extremities after surgery has less to do with shoulder strength 
and more to do with decreased shoulder flexibility. 
 
What this study adds 
 Breast cancer patients undergoing various acute cancer treatments have 
remarkably impaired isokinetic and isometric strength capacity, predominantly 
those receiving chemotherapy in their treatment history. 
 Fatigue resistance of the quadriceps muscle is affected by chemotherapy 
treatment. 
 Less shoulder strength than decreased shoulder flexibility might be the reason for 
dysfunctions in upper extremities after surgery. 
 Identification of breast cancer patients with increased need for individual exercise 
rehabilitation is possible. 
 Resistance exercise may also be applied as a prevention program against muscle 
dysfunction in breast cancer patients at high risk (= receiving chemotherapy). 
 Based in the findings there is a strong need for the implementation of resistance 
exercises in breast cancer patients in the context of chemotherapy treatment. 
 
Exercise training intensity prescription in breast cancer survivors: validity of 
current practice and specific recommendations (III. Publication) 
The ACSM classification in percentages of oxygen uptake reserve (%VO2R), 
heart rate reserve (%HRR), and maximal oxygen uptake (%VO2max) for healthy 
individuals does not seem to elicit the expected exercise intensity for breast cancer 
patients. Prescriptions in %VO2max, according to the ACSM, result in intensities 
slightly lower than intended. In contrast, prescriptions in %HRR, according to the 
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ACSM, result in exercise intensities that are markedly higher than intended, and 
therefore should not be used. Only percentages of maximal heart rate (%HRmax) can 
be used at the end of acute therapy. The high standard deviations of the observed 
percentage values indicate a high individual variability in the relationships between 
%VO2R and the other parameters. However, the use of ventilatory thresholds might 
be better for eliciting defined metabolic strain in this population. Further research is 
therefore required to improve the prescription for exercise intensity in cancer 
survivors. These results can be used to prescribe endurance training intensities for 
breast cancer survivors at the end of acute therapy. They also enable us to compare 
previous exercise intervention trials in breast cancer survivors, in which different 
ways of prescribing intensity were used. 
 
What this study adds 
 The ACSM’s exercise intensity classification for healthy individuals is valid for 
breast cancer survivors at the end of acute therapy only if %HRmax is used. 
 Prescriptions in %VO2max according to the ACSM result in exercise intensities 
slightly lower than intended. 
 In contrast, prescriptions in %HRR according to the ACSM result in exercise 
intensities markedly higher than intended and therefore should not be used. 
 Our results can be used to prescribe endurance training intensities for breast 
cancer survivors at the end of acute therapy. 
 These results also enable comparisons of previous exercise intervention trials 
in breast cancer survivors in which different ways of intensity prescription were 
used. 
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Randomized controlled trial of resistance training in breast cancer patients 
receiving adjuvant radiotherapy: Results on cancer-related fatigue and quality 
of life (IV. Publication) 
Adherence was similar in both intervention arms, with a median attendance 
number of 19 (interquartile range (IQR): 13–23, range 1-24) in the resistance training 
arm and 19 (IQR: 12–22, range 0-24) in the relaxation training arm. In intention-to-
treat analyses, the change in peak torque of isokinetic knee extension muscle 
strength (speed: 60°) was significantly higher in the resistance training group 
(adjusted between-group mean difference of 7.14, 95% confidence interval 2.35 to 
11.94, p=0.004). No significant effect was observed for VO2peak. 
No injuries or severe adverse events related to the interventions were reported 
from either group. The frequency of reported lymphedema did not differ between 
groups. 
Overall, from pre- to post-intervention, total fatigue decreased significantly in 
the resistance training arm, while in the control group with relaxation training there 
was no significant change. Correspondingly, the primary intention-to-treat analyses 
showed significant differences between both intervention groups (p=0.044), with an 
effects size (ES) of 0.33. Considering the different fatigue dimensions, there was a 
significant intervention effect on physical fatigue (p=0.013, ES=0.40), but none on the 
affective (p=0.91, ES=0.02) or the cognitive (p=0.65, ES=0.07) dimension. Significant 
between-group differences favoring resistance training were noted for subscales of 
quality of life (Figure 3), but not for depression. 
A possible mechanism for the effectiveness of resistance exercise in reducing CRF 
among breast cancer survivors is the attenuation of the progressive muscle wasting 
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and disruptions in muscle metabolism that occur with cancer and associated 
treatments (Ryan et al., 2007). 
 
What this study adds 
 Our large randomized controlled intervention trial indicates that resistance 
exercise is safe and feasible as well as efficacious in improving fatigue and 
important components of QoL in BC patients during adjuvant radiotherapy. 
 With fatigue being the most frequent side effect during radiotherapy, this 
finding is clinically meaningful to many BC patients. 
 The physiological effects of exercise add to the psychosocial benefits 
associated with group-based supervised programs. 
 Our results substantiate the claim that resistance training should become an 
integral part of exercise prescriptions for BC patients and that these programs 
should begin parallel to adjuvant radiotherapy. 
 
8.2. Considerations of the study quality 
The research described in this thesis focused on four different exposures: 
cardiorespiratory fitness measured by cardiopulmonary exercise test, muscular 
functions measured by isokinetic device, endurance training prescription, and the 
main results of the RCT on cancer-related fatigue. Beyond the strengths and 
limitations of the studies, this chapter addresses additional issues related to their 
internal and external validity, e.g. methods, study population, outcome 
measurements, and generalizability. 
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8.2.1. Methodological discussion 
RCTs (except systematic reviews) are generally considered to be the most 
reliable form of scientific indication in the hierarchy of evidence that influences 
healthcare policy and practice, because RCTs reduce spurious causality and bias. 
However, RCTs can yield biased results if they lack methodological precision. My 
presented publications tried to report complete, clear, and transparent information on 
the methodology and findings of the study. The descriptive research method and 
cross-sectional analysis used in my publications is also discussed. Therefore, I took 
the most important guidelines for randomized trials and observational research 
(Guyatt et al., 2011; Ryan R, Hill S, Prictor M, & J, 2013; Schulz, Altman, & Moher, 
2010; Vandenbroucke et al., 2014), and put them in the next sections into the context 
of my thesis. 
 
8.2.2. Trial design and registration 
The aforementioned RCT study designs of the BEST and BEATE studies were 
also reported in detail in publications (Potthoff et al., 2013; Schmidt et al., 2013) for 
adequate transparency. Furthermore, my publications I-IV summarized the study 
designs of the BEST, BEATE and INVEST studies. To support the empirical evidence 
and to meet the requirements of journal editors, the RCTs were registered (BEST: 
clinicaltrials.gov: NCT01468766; BEATE: ClinicalTrials.gov NCT01106820). 
 
8.2.3. Eligibility criteria 
The eligibility criteria were reported, along with the reasons for choosing these 
criteria. We were able to ensure that the patients in the BEST study (IV. Publication) 
are similar in age, type and stage of cancer, general health, and previous treatment, 
General discussion
 
146 
so we could be sure that the results of the study are caused by the intervention being 
tested and not by other factors. For the analysis of cardiorespiratory fitness and 
muscle strength and cancer-related fatigue in breast cancer patients (I. – IV 
publications), we reported the eligibility criteria. 
 
8.2.4. Randomization and allocation concealment 
Allocation was done by the biometrician, based on a predetermined list 
generated with a blocked randomization SAS procedure with a fixed block size, 
stratified by age (< 50 / ≥ 50 years) and baseline physical fatigue level (< 14 / ≥ 14). 
We used stratification in the randomization process, as we expect these variables to 
have a major influence on the outcome. To prevent possible bias, study personnel 
involved in the recruitment and the baseline assessment did not have access to the 
randomization lists and were not aware of the block size (Potthoff et al., 2013; 
Schmidt et al., 2013). 
 
8.2.5. Sample size, interventions and outcome 
The number of subjects assigned to control and treatment groups affect a 
RCT's reliability. The primary aim of the RCTs was to compare changes on the 
overall fatigue scale from the baseline to week 13 between the exercise and 
relaxation group. To detect a mean standardized effect size of 0.5 with a two-sided t-
test with significance level 0.05 and a power of 80%, we needed a sample size of 80 
per arm for the BEST study and 50per arm for the BEATE study: 160 or rather 100 
women in total, assuming a maximal drop-out rate of 20% in the BEST study and 
15% in the BEATE study (Borm, Fransen, & Lemmens, 2007). The criteria for 
baseline similarity of groups in the two interventions were fulfilled. We were able to 
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report the outcome measure from >85% of subjects, which is defined as an important 
methodologic quality aspect (Brown et al., 2011). For the reported cancer-related 
fatigue (primary outcome) and secondary outcome analysis in the BEST study, 155 
(97%) patients were included (4th publication). This sample and the testing adherence 
were also large enough to detect clinically relevant intervention effects on the 
secondary outcome, like cardiorespiratory fitness or muscle function. For the 
cardiorespiratory fitness parameters (secondary outcome) at baseline (1st 
publication), we included patients from the two present RCTs (N=222), who had been 
tested before November 2013. For the analysis of the muscle functions (2nd 
publication), patients from the two RCTs and healthy women from the INVEST study 
(n=281) were included. For the analysis of the exercise intensity (3rd publication), a 
subgroup of breast cancer patients (n=52) who had finished their primary cancer 
treatment (surgery + chemotherapy and/or radiation), and had been in the relaxation 
group until November 2013 in order to exclude possible bias due to resistance 
training, was included from the two RCTs as a pilot study. Overall, I am not aware of 
any comparable studies with larger sample sizes. 
All outcome measures were defined, including how and when they were 
assessed. The patients’ fitness was measured with gold standard methods to 
improve the evidence and the intervention program was reported with sufficient detail 
to allow replication, including how and when it was actually administered. Adverse 
events of the tests and the side effects of the intervention were consequently 
reported in the studies with no serious harm overall. 
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8.2.6. Blinding 
Blind testing was not possible to organizational reasons in our exercise 
studies, but participants were not shown their exercise test results until after the 
intervention. For organizational and financial reasons, it was also not possible to 
conceal the subject allocation from the intervention therapists, because they were 
own employees from National Center for Tumor Diseases in Heidelberg, Germany. In 
order to maintain or improve adherence to the training, they reported the absence of 
training problems to the study coordinator, who himself performed assessments. 
 
8.2.7. Intention-to-treat analysis 
We did the analysis on an intention to treat basis, in the sense that we took no 
account of adherence to the intervention. Furthermore, we used all available data, 
keeping participants in their original assigned groups (Hollis & Campbell, 1999). 
 
8.2.8. Generalizability 
The patients were recruited at the National Center for Tumor Diseases (NCT) 
in Heidelberg. These patients are mostly from urban areas, with a higher educational 
level than the population in a rural area. In general, education yields better health 
knowledge which is important to understand the health effects of one’s actions. For 
instance, better educated individuals know more about the long-term health risks of 
overweight, consequences of smoking, alcohol drinking and positive effects of 
physical exercise and sport (Schneider & Schneider, 2012). Higher education and 
better health care infrastructure also means that a higher rate of timely preventive 
medical screenings is possible to detect breast cancer in early stage. 
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Generally, among patients in highly developed countries, the age-standardized 
incidence rate of breast cancer is more than twice as high as in countries with low 
levels of economic development (World Cancer Report 2014). Our participants 
(BEATE: mean 52.7±10.0 years; BEST: mean 55.8±9.1 years) are younger than 
average, as the mean age at diagnosis in Germany (mean 64 years) ("Krebs in 
Deutschland 2009/2010," 2013). One important reason was that we did not include 
patients with metastasized tumors or other severe diseases, because we wanted to 
focus on early stage breast cancer patients not receiving palliative treatment. The 
assessment in patients with advanced breast cancer of our primary outcomes and 
secondary outcomes and the realization of the intervention would not have been 
possible with our capabilities and was not our focus on research. Nevertheless, a few 
studies report benefits of exercise during advanced disease or palliative care (Stene 
et al., 2013). 
Randomization should solve the problem of external validity, but random 
sampling does not guarantee complete generalizability. The generalizability in our 
studies of the relatively homogeneous group of middle-aged, slightly overweight 
primary diagnosed breast cancer patients with mean BMI of 26.3 kg/m2 (higher 
prevalence of overweight and obesity among German women between 50 and 59 
years with a mean BMI of 27,4 kg/m2 (Mensink et al., 2013)) to all breast cancer 
patients might therefore not hold, but the internal validity is very high. However, all 
research suffers from limitations of external validity, whether observational or 
experimental, quantitative or qualitative, since it is necessarily limited by the context 
in which it takes place. 
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Our own analyses about barriers to participate in the BEST study show that 
elderly breast cancer patients, but also those below age 40, patients living alone, 
having a long travel distance, as well as those with worse cancer prognosis, recent 
chemotherapy, being affected by fatigue, or with more comorbidities are less willing 
or able to participate in a RCT (Gollhofer et al., 2015). 
Figure 8. Recruitment flow in the BEST study from July 2011 to December 2011 (Gollhofer et al., 
2015) 
 
The authors reported that the recruitment for the BEST study in the first half year was 
less than 15 % of all breast cancer patients who started radiation (see Figure 11). 
The recruitment in breast cancer patients who started chemotherapy (BEATE study) 
was even lower. One explanation can be that patients with worse prognosis, more 
comorbidities and more intense therapy see more barriers or are not able to 
participate in an additional training program or study. However, it can be speculated, 
that they can benefit from a specific exercise program more than younger participants 
in a better shape. 
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8.3. General conclusions 
The studies described in this thesis provide support for the hypothesis that 
exercise as a modifiable factor can provide improvements in fatigue beyond group-
related psychosocial effects, cardiorespiratory fitness, muscular strength, and quality 
of life. It was essential to evaluate the physical and physiological status of breast 
cancer patients with gold standard methods in order to find the optimal future training 
prescriptions. Although the size of our study did not allow us to draw firm conclusions 
regarding the general advantages of exercise, our findings indicated that exercise 
with adjusted intensity may have bigger effects on health status during and 
potentially after cancer therapy in breast cancer patients. 
 
8.4. Clinical implications: What is the advice for patients with breast 
cancer? 
Cancer-related fatigue has an important role in quality of life, and physical 
performance plays an essential role during breast cancer treatment. These factors 
can be improved by a resistance exercise program, supported by the findings of the 
aforementioned BEST study results during radiotherapy and BEATE study results 
(Schmidt et al., 2014) in patients undergoing chemotherapy. Clinical trials showed 
that full-dose intensity in adjuvant chemotherapy for early-stage breast cancer is 
important for better disease-free survival and overall survival (Bonadonna, 
Valagussa, Moliterni, Zambetti, & Brambilla, 1995; Budman et al., 1998; Wood et al., 
1994). Exercise can potentially improve the chemotherapy completion rate (Courneya 
et al., 2007). Since intervention trials began, about twenty five years ago, only 
minimal adverse effects have been reported (Battaglini et al., 2014). Our results 
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support these findings where no injuries or severe adverse events related to the 
interventions were reported. 
We recommend starting an exercise program as early as possible for breast 
cancer patients. To maintain and/or improve cardiorespiratory fitness, our 
recommendations should be followed for exercise training intensity in breast cancer 
survivors. The considerable clinical extent and importance of muscle dysfunction 
should be met with a resistance training program to maintain and/or improve muscle 
mass, strength, and metabolism during and after cancer treatment. All breast cancer 
patients should have an individual exercise program integrated into their cancer 
therapy process, depending on their secondary illnesses, physical and psychological 
constitution, and different cancer treatments, as well as side effects resulting from 
surgery, chemotherapy, radiation, hormonal therapies, and targeted therapies. 
 
8.5. Scientific implications and future research direction 
The results show that cancer-related fatigue, low physical performance, and 
quality of life during cancer treatment are modifiable in the short term. But there is still 
less knowledge about long-term benefits of an exercise program of 12 weeks 
intervention. Based on the study results, new questions arise for follow-up studies. 
What influence does an exercise program during breast cancer treatment have on 
recurrence or survival rate? Courneya et al. (2014) have begun this kind of research 
with randomized data, and found absolute 8-year survival differences between 7% 
and 9%, but their sample size is clearly insufficient for any definitive conclusions. It is 
also not yet possible to say whether resistance training or endurance training is more 
beneficial for breast cancer survivors, as regards the recurrence rate. To find out, 
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there must be more multicenter trials with large-scale and adequate event rates 
organized with longer follow-ups in future. 
Moreover, the exercise adherence rate in the studies with breast cancer 
patients during cancer treatment was 68.2% - 78.3% of the expected number of 
sessions attended (Courneya et al., 2008; Kim, Kang, Smith, & Landers, 2006; 
Swenson, Nissen, & Henly, 2010). Adherence in the BEST study was relatively high, 
with a rate of 79%. But exercise adherence varies greatly in studies with breast 
cancer survivors, with significantly lower rates after treatment (Kampshoff et al., 
2014). Therefore, all exercise and cancer studies should evaluate adherence, to 
uncover the barriers to exercise and improve training quality. 
Furthermore, the principles of exercise training and thoroughly reporting of all 
components of the exercise prescription should be standard for publications in this 
research field. Only with these requirements will it be possible to create precise 
recommendations for the ideal exercise regime, according the ‘FITT’ format 
(frequency (number of sessions per week), intensity (prescribed intensity of the 
activity), time (duration of each exercise bout) and type (aerobic and/or resistance 
activity)) for breast cancer patients during various treatment phases and after cancer 
therapy (Campbell, Neil, & Winters-Stone, 2011). 
High-quality trials are necessary to understand the mechanisms of exercise 
training on common but currently understudied physiological toxicities, biomarkers, 
and therapy complications (e.g. body composition, cardiotoxicity, peripheral 
neuropathy, thrombosis, bone loss, tumor proliferation, arthralgia, cancer recurrence) 
Additionally, further high-quality studies are necessary to determine the effects of 
exercise on return to work or capacity for caregiving for children/aging parents (Jones 
& Alfano, 2013). 
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